Podcasts about biotherapeutics

Send us a textIn a world of rapid advancements in medical science and biotechnology, bioprocessing is at the forefront of healthcare innovation. Yet, despite remarkable progress, life-saving biotherapeutics remain out of reach for much of the global population.A staggering 80% of patients worldwide lack access to the biotherapeutics they need. While bioprocessing has made impressive strides, the high cost and slow development of these treatments create significant barriers. Addressing these challenges is critical to making innovative therapies widely available.David Brühlmann is launching a special four-part series based on his keynote at the Amphacademy, exploring bioprocessing's revolutionary journey - from the early days of recombinant insulin to today's groundbreaking therapies. This series will also highlight strategies to make these innovations more accessible to patients worldwide.From Standardization to PersonalizationOne major challenge is the shift away from platform technologies. Traditionally, antibodies were produced using standardized CHO cell templates and purification steps, but this approach falls short for new modalities.Personalized therapies further complicate the landscape. Autologous cell therapies, for example, require isolating, cultivating, and reinfusing a patient's own cells. These small-batch processes are labor-intensive, less automated, and often reliant on outdated, paper-driven workflows.Innovations in Bioreactor DesignWith the rise of sensitive cell therapies, bioreactor design must evolve. Unlike CHO cells, these delicate cells require gentler handling environments. Innovations like acoustic wave bioreactors, bionic bioreactors, and specialized cell screws are emerging to optimize cell growth and improve efficiency.The Complexity and Cost of Cell-Based ProductsNew bioprocessing modalities bring greater complexity. Cell-based therapies and cultivated meats are far more intricate than traditional antibody proteins, making scaling production and ensuring quality especially challenging.High production costs further limit access. Even in regions where these therapies are approved, pricing remains a major barrier. Lowering manufacturing costs is essential to democratizing these life-saving treatments.The shift from basic recombinant proteins to complex cell-based therapeutics is just the beginning. Overcoming these challenges - scaling production, reducing costs, and managing complexity - is key to making breakthrough therapies accessible to all.Next step:Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Prof. Mark Smales has been awarded over €3.5 million through the prestigious Research Ireland Research Professorship Programme. Holding a joint appointment between the National Institute for Bioprocessing Research and Training (NIBRT) and the University of Kent, Prof. Smales will lead a five-year research programme focused on revolutionising the manufacturing of next generation biotherapeutics. The project will be based at NIBRT and will support a dedicated research team, including three PhD studentships. Biotherapeutics, such as monoclonal antibodies, gene therapies, and RNA-based medicines, have transformed the treatment of diseases worldwide. Manufacturing these advanced therapies, however, remains complex, inefficient, and costly, limiting their availability and impact. Prof. Smales' research will take a pioneering approach to redefine how these medicines are produced, making manufacturing more efficient, predictable, and scalable. The project will focus on three key areas: Gene Therapy Production - Understanding the biology of the cells and genetic components that underpin gene therapy manufacturing and developing improved production systems. RNA Therapeutics - Investigating how RNA sequences, modifications, and control elements impact their effectiveness as vaccines and therapeutics. Bioprocess Engineering - Applying cutting-edge engineering biology techniques to create new cell factories capable of producing novel format, complex biotherapeutic proteins with improved quality and yield. Commenting on the award, Prof. Smales said: "I am honoured to receive this Research Ireland Professorship award, which will allow us to harness the breadth of world class infrastructure and 'know-how' at NIBRT and across Ireland in the advanced biotherapeutic therapies sector. "IUltimately, this research will deepen our understanding of the science that governs efficiency, predictability and certainty in the design and production of next generation biotherapeutics, so that these can be manufactured at the required quantity and quality for assessment and application in practice. I look forward to working with my colleagues at NIBRT and the University of Kent to deliver real impact for the field and, ultimately, for patients worldwide." CSO & Director of Research and Innovation at NIBRT, Dr. Fiona Killard-Lynch, commented: "Prof. Mark Smales' Research Ireland Research Professorship award is a well-deserved recognition of his leadership in biopharmaceutical research. This funding will enable Mark and his team to drive innovation in gene therapies, RNA medicines, and next-generation protein therapeutics. As a Principal Investigator at NIBRT, this programme will play a key role in advancing cutting-edge biopharmaceutical research, strengthening Ireland's position as a global leader in biopharmaceutical manufacturing. Celine Fitzgerald, Interim CEO of Research Ireland, said: "We are delighted to support Prof. Mark Smales appointment to NIBRT through the Research Ireland Professorship Programme. The programme attracts world-leading researchers to Ireland to build critical expertise and reinforce Ireland's reputation in the global research and innovation landscape. Prof. Smales brings with him over 20 years' experience and expertise in biotherapeutics. "Finding more effective ways to manufacture these therapies will improve outcomes for patients and increase the accessibility of life-changing treatments. Prof. Smales work in this area of translational medicine will help strengthen Ireland's biopharma and biomanufacturing sector, contributing to the advancement of fundamental knowledge within this field." See more stories here.

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. Anastasiou discusses the in-house manufacturing quality advantage, how building that capacity opened the door to important partnering opportunities, the company's preparation for clinical trials and IND submissions, and more. From mastering in-house manufacturing to forging strategic partnerships, Capsida aims to redefine genetic medicine.The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Protalix BioTherapeutics CEO Dror Bashan recently detailed the company's vision for 2025, highlighting advancements in its proprietary ProCellEx platform and its commitment to addressing unmet medical needs. Protalix specializes in producing complex human proteins using plant cell technology, focusing on therapies for Fabry and Gaucher diseases while exploring new opportunities in other therapeutic areas. A key achievement in 2024 was the successful completion of a Phase 1 clinical trial for the company's treatment candidate for gout. Positive trial results have set the stage for a Phase 2 study, scheduled to begin in mid-2025. Bashan also emphasized Protalix's robust financial position, with the company becoming debt-free as of September 2024—a milestone that supports ongoing operations, clinical trials, and pipeline expansion. Protalix is also actively working to extend the reach of Elfabrio, its FDA-approved therapy for Fabry disease. Additionally, the company is leveraging its innovative platform to explore next-generation solutions in renal and other therapeutic areas, aiming to broaden its impact on patient care. Looking ahead, Protalix plans to focus on addressing unmet needs in renal therapies while continuing to build on the success of its current treatments. With a strong financial foundation and a dedication to innovation, the company is well-positioned for transformative growth in 2025 and beyond.

We love to hear from our listeners. Send us a message.Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf' cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message. It might just be coincidence, but it sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, but as he was in the thick of a non-deal road show to execute said plan, Lehmen Brothers collapsed. On this episode of the Business of Biotech, we'll learn in great detail how Altimmune escaped that death knell. Later, he joined his current company, Barinthus Biotherapeutics, mere months before the Covid pandemic. That was shaky for a hot minute, but it turned out fortuitous when, against his better judgment, he enabled a pivot that became foundational to the company's go-forward plan. We'll learn how he flipped the script on that crisis, too. Tune in for these, and other harrowing tales from the trenches. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

“Building relationships and transparent communication are key to successful outsourcing in cell therapy manufacturing,” says Jessica Brantley, Senior Manager of External Manufacturing at Sonoma Biotherapeutics. Jessica Brantley, Senior Manager of External Manufacturing at Sonoma Biotherapeutics, brings a wealth of experience from her roles at Novartis and a decade at Fujifilm Diosynth. Her expertise spans both sides of the outsourcing equation, having worked as a programme manager for a CDMO and now managing external partnerships for a cell therapy innovator. Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. In the latest PharmaSource podcast episode, Jessica explains why getting supplier relationship management right is a crucial strategy for driving down costs and improving efficiency in the fast-moving cell therapy space. Read the interview

Biotherapeutics are transforming healthcare for over 350 million patients globally, tackling everything from cancer and diabetes to rare diseases. Human embryonic kidney (HEK) 293 cells play a key role in the manufacturing of many of these life-changing products. However, they are not without their challenges. In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani, Global Product Manager at Digital Biology Group, discusses the critical need to accurately quantify HEK293 DNA in biotherapeutics to ensure patient safety and regulatory compliance. Gurnani highlights the risks of residual DNA integrating into a patient's genome, potentially causing cancer or genetic abnormalities. She also addresses the limitations of traditional quantification methods like qPCR, which can be time-consuming and prone to errors. We also look at some key innovations in the field, such as Bio-Rad's Vericheck ddPCR HEK293 Residual DNA Quantification Kit that can minimize false positives by specifically targeting HEK293 DNA. For deeper insights into these challenges and innovations, listen to the full episode.See omnystudio.com/listener for privacy information.

Debunking Gym Myths: Muscle Building and Aging ExplainedIn this episode, Paul and Howard discuss common misconceptions about resistance training and gym anxiety, emphasizing the importance of just getting started despite fears of doing exercises perfectly. They highlight the process of muscle synthesis as we age, the minimal risk of injury if weights are managed properly, and the fallacies around the fragility of shoulders. The hosts review a scientific paper on skeletal muscle dysfunction and aging, discuss the role of protein, the potential but cautious use of biotherapeutics like rapamycin, and underline the various benefits of maintaining muscle mass for overall health and longevity.00:00 Introduction and Gear Review Follow-Up00:45 Discussing Skeletal Muscle Dysfunction with Age01:19 Gym Anxiety and Resistance Training02:26 Proper Form vs. Just Doing It04:58 Shoulder Fragility Myths09:38 Protein Intake and Muscle Synthesis16:13 Biotherapeutics and Muscle Maintenance21:00 Conclusion: Keep Moving and LiftingHere is the paper we discuss.Premium subscribers get access to the complete episode, as well as a full transcript. 

This week on Data in Biotech, we're joined by Amy Gamber, VP of Manufacturing at Atara Biotherapeutics, an allogeneic T-cell immunotherapy company developing off-the-shelf treatments to help achieve faster patient outcomes. As a treatment that sits at the cutting edge of options available for cancer and autoimmune disease, host Ross Katz explores how Atara is able to deliver personalized medicine that can be with the patient inside a three-day window.   Amy is clear-eyed about what works well in this field and what doesn't. We gain insight into the complexity of developing this type of cell therapy and the subsequent production challenges of manufacturing at scale. We also cover the manufacturing process, corresponding data problems Amy encounters on a day-to-day basis in her role as VP of Manufacturing, and the strategies she employs to overcome them. Amy discusses the importance of continuous quality monitoring and the need to introduce it from an early stage to see how a program changes through the development phases. She highlights the importance of data as a tool for the ‘detective work' needed to understand where problems arise during manufacturing. Finally, she and Ross close the episode by discussing the future of cell therapy manufacturing, a world where modeling enables predictive QC, the possibilities of AI, and the need to standardize data.  Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in the life sciences. Chapter Markers [1:56] Introduction to Amy and the manufacturing process at Atara, including the importance of cryo storage to facilitate faster patient treatment.   [6:37] Amy and Ross discuss the challenge of donor variability in cell therapy manufacturing and how to manage it. [12:38] Ross asks about scaling cell therapy production and the different considerations for small batch versus commercial-scale manufacturing. [15:47] Amy discusses the importance of continuous quality monitoring, highlighting the value of tracking metrics to ensure quality control and identify improvement opportunities [18:46] Ross moves the focus to automating data collection, as he and Amy emphasize the need for more efficient data access and analysis for timely decision-making. [20:50] Ross and Amy explore the data challenges biotechnology companies face, including the problem with manual data processes, creating feedback loops, and regulatory compliance. [25:16] Amy explains how Atara addressed manufacturing efficiency challenges, the importance of ‘detective work' to understand problem causes, and the process of solving them.  [33:28] Ross and Amy examine how to use data to gather meaningful manufacturing insights, particularly identifying true signals when analyzing small datasets. [36:33] Ross talks about predictive QC measures as the solution to the point Amy makes about being able to guarantee product quality from the outset. [37:31] Amy gives her perspective on the future of biotech manufacturing, the role of AI, predictive modeling, and the need for standardization in the industry. Download our latest white paper on “Using Machine Learning to Implement Mid-Manufacture Quality Control in the Biotech Sector.” Visit this link: https://connect.corrdyn.com/biotech-ml

Corey Goodman, Ph.D., is the managing partner of venBio, a venture capital firm he cofounded in 2011. venBio already has 7 FDA approved drugs on the market, saving and improving lives. Corey spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at U.C. Berkeley, where he was a HHMI Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. Corey co-founded seven biotechnology companies, and led one of them (Renovis) as President and CEO from a private to public company until its acquisition by Evotec. Two of the companies he co-founded have been acquired and three have done IPOs to date.  He then moved to Pfizer, where he was President of the Biotherapeutics and Bioinnovation Center and a member of the executive leadership team. We talk about transformation of UC Berkeley as a startup powerhouse;  his entrepreneurial journey starting with the founding of Exelixis while being a faculty at UC Berkeley; role played by mentors and co-founders; lessons learned from founding startups that founders today could benefit from; changing careers at various stages of his life as he turned 50 and 60 (he recently turned 73); lessons from big pharma; experiences and lessons from partnerships and acquisitions by big pharma; and his experiences investing. Show Notes: Corey Goodman, Ph.D. Corey Goodman's autobiography: https://www.sfn.org/-/media/SfN/Documents/NEW-SfN/About/History-of-Neuroscience/20220914_HON_volume12_goodman.pdf Turn around story of UC Berkeley entrepreneurship: remarkable 10 years People and leadership matter Carol Christ Exelixis: Corey's first startup, co-founded with Gerry Rubin. George Scangos joined the company as CEO in 1996;  Learning from genetic modeling organisms Find a big brother/sister who can help you: Role played by Stelios Papadopoulos and Ed Penhoet Donald Kennedy: Corey's mentor Taking risks at various stages of life: Turning 50, 60, and now 73 Life as an executive at Pfizer and lessons learned in that space Big pharma companies are unbelievably inefficient in early stage drug discovery James Allison: Immune checkpoint inhibitors Importance of academia and startup ecosystem in drug discovery Lessons from big pharma acquiring biotechs: What, when, how and what not to do Lessons learned from biotech partnering with big pharma: Don't partner on everything- keep some to yourself Operator VCs: Investors/board members who went through building companies are more valuable than those who come from consulting backgrounds Building teams Transition to Pfizer and out: “Come change the world” Launching VenBio: Everybody's voice matters Investment thesis

John Celebi, the President and Chief Executive Officer of Sensei Biotherapeutics, emphasizes the need to develop better patient selection strategies and next-generation therapeutics for cancer patients. Through their Tumor Microenvironment-Activated Biologics platform (TMAb), Sensei develops conditionally active therapeutics designed to be active only within the low-pH tumor microenvironment.  Current pipeline candidates are designed to be active only within the low-pH tumor microenvironment and show potential to overcome the challenges of VISTA, a promising checkpoint target. John explains, "As an industry, we have some tough choices. Other strategies, both within and outside of IO, have made much better progress in targeting which patients will respond and which patients won't respond to treatment. Those are decisions that we have to make as an industry to keep up." "The second one I would point to is that we're now in a decade after the first immuno-oncology drug approval. And so, we have a whole generation of patients now that have been exposed to checkpoint therapy, and that are now many of whom resistant to checkpoint therapy. We call that acquired resistance. And so the game has really changed. It's an open question: whether the first PD-1 drugs would be approved today if all of those patients had been treated with some other checkpoint therapy prior to it raises the bar. This means new strategies are needed to treat patients with acquired resistance to immunotherapy."   "One of the interesting things about VISTA is that it does play a key role in the tumor microenvironment. The tumor microenvironment is unique because it's an environment inside the body in which cells proliferate very rapidly. That leads to a whole host of subsequent changes that affect the outcome of therapy, the fact that when cells are dividing rapidly, the pH in the area tends to drop, and it becomes more acidic. And that's directly related to the function of VISTA. It's one of the things that makes VISTA unique because VISTA is only activated as an immune checkpoint under lower pH conditions." #SenseiBio #ImmunOncology #PatientSelection #Immunotherapy #Cancer #Tumors #ImmuneCheckpointTargets #VISTA SenseiBio.com Download the transcript here

John Celebi, the President and Chief Executive Officer of Sensei Biotherapeutics, emphasizes the need to develop better patient selection strategies and next-generation therapeutics for cancer patients. Through their Tumor Microenvironment-Activated Biologics platform (TMAb), Sensei develops conditionally active therapeutics designed to be active only within the low-pH tumor microenvironment.  Current pipeline candidates are designed to be active only within the low-pH tumor microenvironment and show potential to overcome the challenges of VISTA, a promising checkpoint target. John explains, "As an industry, we have some tough choices. Other strategies, both within and outside of IO, have made much better progress in targeting which patients will respond and which patients won't respond to treatment. Those are decisions that we have to make as an industry to keep up." "The second one I would point to is that we're now in a decade after the first immuno-oncology drug approval. And so, we have a whole generation of patients now that have been exposed to checkpoint therapy, and that are now many of whom resistant to checkpoint therapy. We call that acquired resistance. And so the game has really changed. It's an open question: whether the first PD-1 drugs would be approved today if all of those patients had been treated with some other checkpoint therapy prior to it raises the bar. This means new strategies are needed to treat patients with acquired resistance to immunotherapy."   "One of the interesting things about VISTA is that it does play a key role in the tumor microenvironment. The tumor microenvironment is unique because it's an environment inside the body in which cells proliferate very rapidly. That leads to a whole host of subsequent changes that affect the outcome of therapy, the fact that when cells are dividing rapidly, the pH in the area tends to drop, and it becomes more acidic. And that's directly related to the function of VISTA. It's one of the things that makes VISTA unique because VISTA is only activated as an immune checkpoint under lower pH conditions." #SenseiBio #ImmunOncology #PatientSelection #Immunotherapy #Cancer #Tumors #ImmuneCheckpointTargets #VISTA SenseiBio.com Listen to the podcast here

In this podcast, Scott and John will discuss the LC-MS techniques that have been applied for the bioanalysis of biotherapeutics.The episode explores the following:The impact that mass spectrometry is having in the biotherapeutics and biomarker spaceThe rationale behind the use of LC-MS for certain biomarkers and how sensitive LC-MS assays can be developed (and the practical limits for lower limits of quantification that can be achieved)Developments in mass spectrometry that are expected to benefit the analysis of biomarkers and for biotherapeuticsSpeaker:John Mehl – Consultant John Mehl is currently consulting and previously worked as a director at GSK, leading the Protein MS group within the Bioanalysis, Immunogenicity and Biomarkers (BIB) department, Collegeville, PA. The group developed LC-MS assays for quantitative & qualitative analysis of biopharmaceuticals, protein & small molecule biomarkers and for the determination of in vivo protein turnover kinetics to support preclinical and clinical studies. Prior to joining GSK, John worked for BMS where he was a Sr. Principal Scientist focused on biomarker & large molecule quantification and characterization using MS.  John has a PhD degree in analytical chemistry from Vanderbilt University, postdoctoral training in protein MS from MIT and an MBA in business management from Temple University.  Before joining BMS, John worked for Merck in different analytical research areas including proteomics, small molecule DMPK, large molecule immunoassay method development and vaccine and biologics protein characterization, spanning both discovery and regulated laboratories.  He has published extensively on the use of hybrid LC-MS for both large and small molecule quantification.Stay tuned for more podcasts in our Pharmaron DMPK Insights Series!

In this episode of Engaging Alternatives Spotlight, Elana Margulies-Snyderman, Director, Publications, EisnerAmper, speaks with Bibhash Mukhopadhyay, Managing Partner, Sound Bioventures, a venture capital fund that invests in about-to-be clinical or clinical stage private companies in Europe and the U.S. developing therapies in specialty therapeutics areas. Bibhash shares the outlook for VC investing those companies including the greatest opportunities and challenges, how the firm integrates ESG, DEI and more.

During the COVID-19 pandemic, there was a reduction in the availability of nonhuman primates available for conducting nonclinical toxicity assessments, and as a result, the FDA released a guidance in 2022. This sparked interest in evaluating the feasibility of performing safety studies with alternative nonrodent species or other models. This podcast is the first in a series of several podcasts sponsored by ACT, in which experts in the industry are interviewed about their experiences working with these nontraditional models.

Going the "industry" route doesn't always mean Big Pharma! Learn from alumna Léolène Carrington, PhD, what it is like to work for a smaller company and how your love of science and learning can dictate your career.   

Viraj Mane is the co-founder & Chief Scientific Officer at Lactiga, an award-winning, venture-backed biotherapeutics company treating and prevent infections using an unusual but genius method…human milk. That's right, Lactiga uses human breast milk to battle even the world's most dangerous pathogens. It turns out, some people would benefit tremendously from what's found in the breast milk of other humans, and if done right, the power of this novel approach is astounding. Viraj has a PhD in Human Genetics from Baylor College of Medicine, and has completed two post-doc fellowships, including one for the U.S. FDA. After he became a father, he had a strange but brilliant idea after seeing excess breast milk stored in the freezer. I know you'll love this episode from a very smart person. ➡️ https://lactiga.com/ ➡️ https://rosspalmer.com/viraj-mane ➡️ Follow me on Instagram: @therosspalmer ➡️ Subscribe on YouTube: @therosspalmer

Ever wondered about the people who are leading the fight against cancer, developing groundbreaking treatments, and changing lives? Meet Frank Boriello, the mind behind SUPLEXA cell therapy, and the CEO and founder of Alloplex Biotherapeutics. In our conversation, Frank shares the personal backstory that sparked his quest to revolutionize cancer treatment and frames the scientific journey that led to SUPLEXA. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.

This episode features an interview with Dr. Paul Rennert, co-founder, CEO and CSO of Aleta Biotherapeutics, an immuno-oncology company focused on multi-antigen targeting solutions designed to enhance the action of CAR T cell therapies in B cell lymphoma, B cell leukemia and multiple myeloma, as well as non-B cell cancers such as acute myeloid leukemia (AML) and solid tumors such as breast cancer, gastric cancer and pediatric brain tumors.Dr. Rennert spoke to Xtalks about CAR T cell engagers that Aleta is developing for both B-cell and non-B cell cancers. The company was recently granted clinical trial authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its investigational biologic CAR T-Cell engager ALETA-001. It will be evaluated in a Phase 1/2 clinical trial for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T-cell therapy.  Dr. Paul Rennert is a noted research scientist and biotechnology executive with extensive strategic and leadership experience. After launching successful new biotech companies from 2012 to 2016, he co-founded Aleta Biotherapeutics. Dr. Rennet's ability to work broadly across the industry grew from his outstanding early career at Repligen and Biogen, highlighted by multiple successful drug-development campaigns, over 50 patents filed and granted, and approximately 100 peer-reviewed publications. Tune into the episode to hear more about Dr. Rennert's work in advancing CAR T cell therapies in oncology.For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Ever dreamt of making lucrative stock market investments but unsure where to start? Well, your wish is our command! Let's take a thrilling ride through the bustling stock market where we'll shine a spotlight on some promising stocks such as Everi, Applied Digital, and Arcutus Bio Therapeutics. These companies are making waves and we'll dive deep into why they're our top picks. Just a heads up though - investing in stocks can be a bumpy ride, so buckle up and stay informed about possible risks and downturns.Tomorrow, shift gears with us as we turn the pages of 3 of Donald Trump's books - 'Why We Want You to Be Rich', 'Think Like a Billionaire', and 'How to Get Rich'. Whether you're a budding entrepreneur, a seasoned business enthusiast, or just intrigued by the mogul's secrets to financial success, we guarantee nuggets of wisdom that could potentially change your life. Each book is a treasure trove of insights and we'll walk you through the key takeaways that could be game-changers for your personal and professional journey. So, don't forget to tune in for the next episode, where we'll continue our exciting literary adventure.

Dr. Edith Perez, Chief Medical Officer at Bolt Biotherapeutics, describes the innovative approach Bolt is taking to bring together the precision of antibodies against the tumor with the power of the innate and adaptive immune system by activating the immune system at the tumor site.  This approach can minimize side effects from systematic activation of the immune system and reinforce long-term anti-tumor efficacy. Edith explains, "The myeloid cells are a wide range of cells in the body, and initially, the myeloid cells can start attacking the tumors right away. But as important, or even more importantly, is that they secrete the cytokines and chemokines to teach the T-cells to essentially develop an immunological memory to be able to fight these foreign bodies for a long time."  "First of all, there are the abnormalities of the tumor themselves, and we target those with monoclonal antibodies. Then we actually link that with what we call a non-cleavable and non-cell permeable linker. Again, the idea is to bring the activation of the immune system right at the site of the tumor, which could be dramatic for humans."  "So these monoclonal antibodies essentially find the tumor cells because the tumor cells are circulating, they're in the body, so they latch onto these proteins in the membrane and with our compound, with our Boltbody compounds. What we have here is the attachment of the monoclonal antibodies with what we call the linker payload. The payload is really the activation factor of the immune system. We bring that activation of the immune system, tied into the monoclonal antibody, to the site of the tumor. That way, we can be very precise related to where the activity of the compound will occur." @BoltBio #BoltBio #ISAC #Immunotherapy #Oncology #Tumors #ImmuneSystem boltbio.com Listen to the podcast here

Dr. Edith Perez, Chief Medical Officer at Bolt Biotherapeutics, describes the innovative approach Bolt is taking to bring together the precision of antibodies against the tumor with the power of the innate and adaptive immune system by activating the immune system at the tumor site.  This approach can minimize side effects from systematic activation of the immune system and reinforce long-term anti-tumor efficacy. Edith explains, "The myeloid cells are a wide range of cells in the body, and initially, the myeloid cells can start attacking the tumors right away. But as important, or even more importantly, is that they secrete the cytokines and chemokines to teach the T-cells to essentially develop an immunological memory to be able to fight these foreign bodies for a long time."  "First of all, there are the abnormalities of the tumor themselves, and we target those with monoclonal antibodies. Then we actually link that with what we call a non-cleavable and non-cell permeable linker. Again, the idea is to bring the activation of the immune system right at the site of the tumor, which could be dramatic for humans."  "So these monoclonal antibodies essentially find the tumor cells because the tumor cells are circulating, they're in the body, so they latch onto these proteins in the membrane and with our compound, with our Boltbody compounds. What we have here is the attachment of the monoclonal antibodies with what we call the linker payload. The payload is really the activation factor of the immune system. We bring that activation of the immune system, tied into the monoclonal antibody, to the site of the tumor. That way, we can be very precise related to where the activity of the compound will occur." @BoltBio #BoltBio #ISAC #Immunotherapy #Oncology #Tumors #ImmuneSystem boltbio.com Download the transcript here

In this episode of the Life Science Success Podcast my guest is Pavel Printsev.  Pavel is the Director of Business Development at Bridge Biotherapeutics. Prior to joining Bridge in early 2021 he was working at a South Korean VC firm. Pavel's academic background is in Organic Chemistry and worked as a Research Scientist for several years. Since then, he has been active in advancing scientific development through global partnership, collaboration and investment between South Korea and the rest of the world.   Bridge Biotherapeutics is a small to mid-size Biotherapeutics company founded in 2015. They have clinical-stage assets in nonsmall cell lung cancer, ulcerative colitis, and idiopathic pulmonary fibrosis. They also acquired a next-generation biosensor detection company, which is a thousand times more sensitive than the current commercial ECL biosensor device. Bridge Biotherapeutics is focused on maximizing resources and following the path where they see the most opportunity. Pavel Printsev is inspired by people who have become masters in their respective fields and are dedicated, motivated, ambitious, and do not give up. Concerns include the gap in research and unmet medical needs for indications that may not be profitable. Pavel is excited about the advancements in AI and deep learning, gene editing, and precision medicine.

In episode 1 of our yet-to-win award podcast, we talk to Dr. Sandeep Kumar, Distinguished Research Fellow in Biotherapeutics at Boehringer Ingelheim about how he uses computers to help develop and deliver biopharmaceuticals and his thoughts on the increasing importance of computational methods in drug discovery.  It gets controversial at times, so, you know, just a warning on that. See more: Computational Antibody Discovery: State of the Art: https://www.antibodysociety.org/computational-antibody-discovery-state-of-the-art/

In this episode of Life Science Success, my guest is David Baram.  David Baram is the co-founder and CEO of Emendo Biotherapeutics. David has taken Emendo from the pre-seed stage through multiple financing rounds and a successful acquisition in 2020. Don Davis, PhD, MBA interviews David Baram, PhD, CEO of Emendo Biotherapeautics Mendo is focused on developing gene editing therapies for rare and prevalent diseases, including cardiovascular diseases. They discuss the challenges of managing a company with different interests at play, including investors and patients. They touch on the potential of AI and the need for regulation and control. David shares his motivation and excitement in achieving his goals and seeing his inventions materialize.

[Ep12] Have you ever considered biotherapy options to help heal wounds? Let's get more specific - what are your thoughts on maggot therapy? Do you know how it works, or what kinds of patients might benefit from maggot therapy? Before you brush off the idea of medicinal maggots, listen in on our conversation about why they are a fantastic tool to consider for wound care - and more - on this episode of High-Fidelity Conversations! Ronald Sherman, M.D., M.Sc., DTM&H, is an expert in maggot therapy, as well as the Director of the BioTherapeutics, Education and Research (BTER) Foundation in Irvine, California. The BTER Foundation is a not-for-profit public charity that supports patient care, education, and research in maggot therapy and symbiotic medicine.  Listen in on our conversation to learn more about: What is the process like when applying maggot therapy? What do the maggots actually do to the dead tissue? How are the maggots made ready for human use? How are the maggots kept on the wound? How do you dispose of the maggots after using them? Do maggots encourage new tissue growth? Can you use maggots with other wound therapy techniques? And more! Quick Links: Linktree: Link to PDFs relating to maggot therapy BioTherapeutics, Education, & Research Foundation International Biotherapy Society A Complete Guide to Maggot Therapy (free electronic book) Do you have ideas for future guests or topics on this podcast? Maybe you have some thoughts on how to improve the show? If that sounds like you, take a moment to answer the 3 questions on our anonymous feedback survey!Podcast artwork was made with the awesome resources from CanvaMusic for the show was obtained from PixabayEmail the show at hfconversations@gmail.com

In December 2022, Atara Biotherapeutics' Ebvallo received European Commission approval as the first-ever therapy for adults and children with EBV+ PTLD. The ground-breaking approval represents the first approval of an allogeneic T-cell immunotherapy ever, globally. Atara Bio's CEO, Pascal Touchon, talks to Cell & Gene: The Podcast's Erin Harris about the biopharma's path to regulatory approval, commercialization plans for Ebvallo, an in-depth look at EBV+ PTLD, the connection between EBV and serious diseases like multiple sclerosis (MS), and much more.

In healthcare, they say the only constant is change. Medical practices and treatments are always evolving, and today's guest is on the cutting edge of an exciting development. Today we're sitting down with Dr. Eddie Sullivan, co-founder, President and CEO at SAB Biotherapeutics. Eddie served in biopharma leadership positions for more than 25 years, and prior to joining SAB, he was CEO of Hema Tech, where he led initiatives to develop infectious disease, cancer, and autoimmune immunotherapies. A recognized thought leader in antibodies in transgenic animals, Eddie serves on the board of directors for the Biotechnology Innovation Organization, he's earned two PhDs in health science administration and reproductive physiology, and he holds an MS in reproductive physiology and molecular biology, and a BS in Animal health sciences.On the show, we talk to Eddie about SAB's polyclonal antibody research, perceptions about this research in the biotech world, and the future of fighting diseases. Highlights: Eddie's path to the Biotherapeutics field (3:04) Founding SAB and the immunotherapy industry (3:41) How SAB uses cows for research (4:59) SAB's take on the COVID vaccine (8:43) Perceptions of monoclonals vs. polyclonals (13:27) Slow growth in polyclonal research (16:57) SAB's work on Type 1 Diabetes and other disease treatment (20:13) What Eddie is excited about in the future for the field (26:19) The biggest challenge in biotech (27:10) Links:ICR TwitterICR LinkedInICR WebsiteDr. Eddie Sullivan on LinkedInSAB Biotherapeutics on LinkedinSAB Biotherapeutics WebsiteFeedback:If you have questions about the show, or have a topic in mind you'd like discussed in future episodes, email our producer, marion@lowerstreet.co.

SPECIAL EDITION: BOB@JPMBolt Biotherapeutics CEO Randall Schatzman, Ph.D. and CMO Edith Perez, M.D. are no strangers to the Business of Biotech, having previously joined us on episodes 14 and 18, respectively. The last time we spoke with Dr. Schatzman, he was preparing the company for its initial public offering. We caught up with him and Dr. Perez at the JP Morgan Healthcare Conference in San Francisco last month for a conversation on the IPO process, the impacts it's had on the go-forward plan at Bolt Bio, the company's clinical progress, and its collaboration strategy moving forward. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

The Life Sciences Industry is ready to face communication, regulation, and innovation challenges. In this episode, Matt Neal, Senior Director of Regulatory Affairs Operations at Atara Biotherapeutics, talks about his work introducing innovative technology for data management to evolve the regulatory operations and submissions space. Matt also explains why he believes that communication with the patient community, bringing company information to an accessible platform, and standardizing the language in work environments can accelerate the innovation process in life sciences. Tune in to learn how Matt Neal is getting rid of the waste in Life Sciences to improve the industry! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Jeff Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus at the Diabetes Center of The University of California, San Francisco.Bluestone is a highly accomplished scientific researcher and international leader in the field of immunotherapy and has published more than 500 papers over nearly four decades focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development and commercialization of multiple immunotherapies, including the first FDA-approved drug targeting T-cell costimulation to treat autoimmune disease and organ transplantation and the first FDA-approved CTLA-4 antagonist drugs for the treatment of metastatic melanoma. He was part of the team of early developers of a novel anti-CD3 monoclonal antibody, now called teplizumab, a pro-tolerogenic drug that has shown clinical activity in type 1 diabetes, psoriatic arthritis, and the reversal of kidney transplant rejection. In addition to his research, Bluestone was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy. He recently led the Parker Institute for Cancer Immunotherapy as president and CEO. He served as a member of the Blue Ribbon Panel, a board of scientific experts appointed by then Vice President Joe Biden to guide the NCI Cancer Moonshot Research Initiative. He was also the Ludwig Professor and director of the Ben May Institute at The University of Chicago and served as a senior investigator at the NCI. Bluestone holds a BS and an MS from Rutgers University and a PhD in immunology from the Weill Cornell Graduate School of Medical Sciences.Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Comparability studies are a significant issue for those working in biotherapeutics development, as undetected product changes are considered high risk. Listen as Kevin Hennegan, Lisa Erickson and Sarah Roemer take us through several considerations when Playing the Comparability Game in Biotherapeutics Development.  

Tune into this 9-minute chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc. (NYSE: PLX).

When we think about the future of medicine, we think about companies like Iovance. Iovance Biotherapeutics, Inc. is pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. Their lead, late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. At this year's ISPE Annual Meeting in Orlando FL, I had the chance to sit down and talk about some of the things that Iovance is doing with Sumit Verma, Senior Vice President Global Strategic Manufacturing. It was obvious to me that not only is Sumit very engaged on the "facility" level of what needs to happen to make a successful facility for our modern therapeutics, but he is passionate about the patients that Iovance is helping. This isn't just a job, its a mission. The future of cell and gene therapy is a fascinating one, and what Sumit and his team at Iovance Biotherapeutics are doing will have monumental, life saving effects in the lives of so many where before there was little hope. Listen in our conversation! Modern Biopharma Podcast Say hi on LinkedIn

For episode 3, we sit down with Frank Watanabe, President & CEO at Arcutis Biotherapeutics.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO. Episodes launch weekly on Tuesdays.To view the full episode transcript, click here.

Sab Biotherapeutics CEO Eddie Sullivan joined Steve Darling from Proactive to share news the company has present interesting data with its novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies. Sullivan telling Proactive showing its fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses. Sullivan says this shows the power of polyclonal antibodies to neutralize highly mutating viruses and what sets SAB's novel therapeutic products apart from others. #proativeinvestors #SabBiotherapeutics #nasdaq #sabs

Through research, clinical trials and biomanufacturing, Mayo Clinic's Center for Regenerative Biotherapeutics is working to develop new types of medicines derived from the human body to treat chronic and age-related diseases. Biologics are therapies that come from human sources — cells, blood, enzymes, tissues, genes or genetically engineered cells — for use in medicines. Biomanufacturing is focused on manufacturing commercial grade biologically based medicines for treatment. Some examples include the use of stem cells, gene therapy and cell therapy, and 3D printing of tissues and organs."The important thing is that there's an opportunity to use these type of therapies to cure rather than just treat patients as we move forward looking at different ways of being able to use these products," says Dr. Julie Allickson, the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics. "It's definitely a bright future." Dr. Allickson also is the Otto Bremer Trust Director of Biomanufacturing and Product Development in the Center for Regenerative Biotherapeutics.Mayo Clinic is working to move cellular discoveries from the lab to clinical trial and into commercially available therapies. To move technologies forward, partnerships are key.  Mayo Clinic has formed a strategic collaboration with National Resilience Inc. to establish Rochester, Minnesota as a center for biomanufacturing regenerative technologies. Mayo also has manufacturing facilities in Jacksonville, Florida and Phoenix.Recently, Mayo Clinic, Hibiscus BioVentures, and Innoforce announced the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet patient needs. All three organizations have a financial interest in the Mayflower collaboration. Mayo Clinic will use any revenue it receives to support its nonprofit mission in patient care, education and research."There is a lot of investment in the field," says Dr. Allickson. "And Mayo Clinic is certainly prioritizing this across the enterprise, to allow the patients here to have treatments focused on rare and complex diseases. Here at Mayo Clinic, we want to make sure that that happens."On the Mayo Clinic Q&A podcast, Dr. Allickson discusses the near- and long-term future of biomanufacturing and biotherapeutics.

Can a chemical found in citrus fruit curb cancer and save lives through early detection? Today on the show, we'll talk about the possibilities with Dr. David Suhy, Cofounder and Chief Medical Officer of Earli. Earli was founded with the mission to make cancer a benign experience by catching and curing it early. According the the American Cancer Society, 40% of people will be diagnosed with cancer at some point in their lifetime. And a third will die from it. What if there was a way to detect and confirm the presence of cancer by inducing synthetic biomarkers? You could catch cancer when it's most treatable and save countless lives. Learn more about this exciting technology and get inspired by David's insights. About David SuhyDr. David Suhy is the Chief Scientific Officer and Cofounder of Earli. He is a gene therapy expert, experienced in bio ventures both private and public. He has led gene therapy ideas from inception through Phase 2 clinical trials, and is recognized as a leader that science teams love to work with.Before Earli, he was the CSO at Benitec Biopharma where he oversaw development paths for products in or near term clinical studies, including Hepatitis C Virus (HCV), Head and Neck Squamous Cell Carcinoma (HNSCC), and Oculopharyngeal Muscular Dystrophy (OPMD). He developed the first non-withdrawable, systemic RNAi compound used clinically in human subjects. He previously held scientific leadership roles at Tacere Therapeutics, Takara Bio, Anatara and PPD.  He earned his PhD in Biochemistry, Molecular Biology and Cell Biology  from Northwestern University and completed his post doctoral training at Stanford University.He's a father to three teenagers, and he loves making pizza in his large wood-fired oven in his backyard. David is married to a neuroscientist, Dr. Joyce Suhy, who knows the risks of science, and is convinced that with David's passion, Earli will accomplish its purpose.About EarliEarli was founded in June of 2018 by Dr. Sam Gambhir, Cyriac Roeding and Dr. David Suhy. Earli is developing  a technique, originally from Stanford University, to trigger the production of synthetic biomarkers as a means to detect, target and destroy cancer cells. Earli is currently enrolling for their clinical trial in Australia. LinksDavid Suhy | LinkedIn:https://www.linkedin.com/in/davidsuhyEarli:https://www.earli.comEarli Clinical Trial News:https://bit.ly/3A3bQ53Sam Gambhir | Wikipedia:https://en.wikipedia.org/wiki/Sanjiv_Sam_GambhirQualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez 

Drug developers face long odds and complex regulatory challenges when it comes to crafting a suitable candidate. In fact, only one of every 10 drug candidates gain regulatory approval, and when they do, it takes an average of 14 years and costs well over $2 billion.   So what makes for a successful candidate? It starts with a suitable screening platform that identifies targets and the molecules that bind to them to create a therapeutic response. Retrogenix is one such platform that the top 20 drug developers in the world currently use to increase their chances of success thanks to its unique technology that doesn't require animal models or human tissue to evaluate effectiveness.   Join us to find out how Retrogenix works to identify targets, accelerate drug development, get vulnerable patients the therapies they need more quickly, and adapt to meet the growing demands of regulatory agencies. Show Notes  Charles River Acquires Retrogenix  Retrogenix Cell Microarray Technology  De-risking Therapies and Vaccines for Use During Pregnancy  Assessing ADC Anticancer Therapeutics via Antibody Specificity Screening  Screening and Profiling Assays  Off-Target Screening Cell Microarray Assay   Webinar: Building a comprehensive lead enabling library   Poster: Off-target Assessment of Biotherapeutics for us During Pregnancy  Case Study: Antibody Drug Conjugate Off-Target Binding Screen

At The Ottawa Hospital, we are harnessing biology to fight disease. Our hospital is home to a state-of-the-art Biotherapeutics Manufacturing Centre (BMC). It's our unique contribution to one of the most advanced areas of scientific innovation. Jen Quizi is the Director of the Biotherapeutics Manufacturing Centre in the virus manufacturing facility and is an investigator at our research institute. She takes us behind the scenes of the BMC to learn more about our best-kept secret. (24:12)

Kevin Lee, CEO of Bicycle Therapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Bicycle Therapeutics is working on developing a new class of medicines, called Bicycles, for diseases that are underserved by existing therapeutics. 

BioBoss host John Simboli speaks with Reenie McCarthy, CEO of Stealth BioTherapeutics, headquartered in Needham, MA.. Hear Reenie's thoughts about leadership in biopharma and how Stealth Biotherapeutics is working on developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases.

Episode Summary:Elon Musk Sells $5 Billion of Tesla Shares$500 Shiba Inu Giveaway Guests:Ben Rabizadeh StoryTrading 10:00Vivi Biotech Queen https://twitter.com/Biotech_SD 24:00Zandy Forbes, Ph.D. President & CEO of MeiraGTx (NASDAQ: MGTX) 41:00Ronen Samuel, CEO of Kornit (KRNT) 55:00Scott Mathis, CEO and Chariman of Guacho Holdings $VINO 70:00Renato Capelj, Benzinga, Physik Invest 110:00https://physikinvest.com/Hosts:Spencer IsraelTwitter: https://twitter.com/sjisraelAaaron BryTwitter: https://twitter.com/aaronbry5Subscribe to all Benzinga Podcasts hereClick here for BENZINGA TRADING SCHOOL Get 20% off Benzinga PRO here Become a BENZINGA AFFILIATE and earn 30% on new subscriptionsDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Unedited Transcriptwe got a lot of guests today. Here's that's what I said. Here's what we got. We got Ben from story trading in like eight minutes. We've got Vivi biotech, uh, or the Bio-Queen at, uh, 1215. We've got Zandi Forbes from Mira GTX. She's a presidency yet.We're talking gene editing at 1230. We got Ronan Senor from Coronet digital we're talking, uh, fashion and the fashion supply chain at 1245. Did I get all that right? As far as timing goes. Yep. We got Scott Mathis from Gaucho holding sicker V I know, uh, at one and that Renato, uh, Capella, he is a Benzinger writer and also does some really, really cool options trading on the side.Uh, he'll be on the show at one 30. So we got what we got. 1, 2, 3, we got six guests today. We have all that's a lot, frankly. Uh, maybe a few too many, but nonetheless, here we are. So before we get to those guests, uh, we're going to talk about what's what's moving. We're going to talk about, uh, crypto. We're going to do a guest that sharp sediment.Cause we got some good feedback from that yesterday. So, um, AB where should we start? Um, well, let's start with just looking at the overall market. Spencer. I see Christian in the chat asking who do we have on for a guest today? You just ran through them, but you can also check the description in the YouTube, uh, the YouTube description for the guests for the day.Um, and shout out to the chat yesterday. We had some good trade ideas thrown out in the chat yesterday. We did, uh, easy Mike was talking about Uber puts. I played those. They were up nicely. Um, and we were talking about playing Disney for a big move on either side. We got talked out of it by our main man, Nick Shaheen.But yeah, I don't know. Maybe we should have done it. Yeah. I felt bad about that one going and they got talked out of it, but, uh, you know, it was a pretty brutal quarter. So, um, anyway, I don't even know why I look at Disney it's in my never sell portfolio. That's my first mistake is don't look at and stuff and your never sell portfolio.Otherwise you're just giving yourself anxiety. Rowan DAS pips is saying audio levels. Are we good, Bruce? Or Ron? Are you awake? I'm here. Okay. Oh, he's coming through us through the sky. I did not know that was coming from Terminator. I'm hanging out on the background, like a good idea. Hey, uh, while we figure out those levels, if you all want to do a solid, as DK suggested and hit that like button ladies and gentlemen, we'd appreciate that.Thank you very much. Um, Hey, what's do a guest, that chart segment. We're going to start doing this every day yesterday. Wasn't it easy one a B I don't even remember what it was. It was D whack. Oh yeah. That was that. That was yours. Full disclosure, I guess the one today. No, because I changed it. Shoot. So beforehand Spencer showed me the guests that chart and I guessed it and he didn't like the fact that I got it so easily.So he went out and picked a new one. I don't know what it is. I went out and I picked her from, Ooh, this will be a good drawer. And then he gets to like right away. So it's not a firms that don't get that, um, drop your answers on the chat and whoever's right. Uh, email us afterwards and we'll send you some swag.Um, here is two days chart of the day. This is going back to like February, or actually this is going back to the start of the year. This is going back to the interests of the start of the year. Now I will give you some hints because otherwise it'd be impossible. I feel like, um, in some respects, this is a technology stock in some respects.Oh man, we can have a winner already. Holy moly. Christian Gallagher. Wait, it was PayPal. This is PayPal. How so are we looking at weekly candles right now? Is this a daily PayPal has gotten beat up over the past month or so it looks like, yes, it has gotten beat up is, is, is, is a nice way of putting it, but yes, Christian Gallagher.Did anyone yesterday? No, Frendo on yesterday. Christian email us shows app benzinga.com. Hey, why is PayPal down so much? Didn't they just announce a Venmo, Amazon integration. So yeah, you would think that tell me you don't own PayPal or maybe you do and you don't know it. Um, I think in my like real portfolio, the one that I don't manage it's in there scourge.It's too easy with showing prices. Well, that's an idea. I take the price off ridiculously hard, but we could do that. Should I buy? I like calls on PayPal. No, it's gotta be coming back up at some point, right? That's one way of putting it. Um, you want to throw out like, uh, you know, you want to buy the, the, the, the, the two 80 strikes expiring and like six months.Really worth looking at. I'm sure it's not very much money. I do think though we have to, um, you know, keep up, like if we start doing obscure biotech stocks, you know, it'd be nearly impossible. So what we'll probably try to stick to, I dunno, S and P 500. Yeah. That's, that's, that's a good plan. Stick to the S and P 500.So we're going to do this everyday. Christian email us shows up and it's going to come. We will hook you up with some schwag before we go to our first guest AB I seem working backstage. Let's do our first crypto update of the day. Sure. Yeah. So yesterday Bitcoin spiked on the CPI data and then gave up all those gains and more.Let's take a look today to see how the, the crypto markets are responding to that yesterday. Uh, we, we have a lot of people in the chat that have been asking kind of how are they supposed to be trading crypto right now? So I know you and I, Spencer are in that boat where we're just like adding Ethereum and not really touching it or selling it.I haven't even added recently. It's been a while for me. I hadn't bought a theorem. I wanted the board. So yesterday, w like I've mentioned, once that CPI data came out, Bitcoin spiked and actually hit brand new, all time highs, um, gave all those gains up is currently trading about $65,000 a coin down 4.8%.Ethereum is also down, albeit not as much Ethereum currently, right around $4,800. So we talked about that $5,000 level being a big level for Ethereum. I think once we see a theory and finally breakthrough that $5,000 level, we can really see it run. Um, but yeah, everything pretty much in the red, like you can see from this heat map Sheba, he knew though in the green up 5%, um, we're actually going to have a big Shiba Inu guest on the show tomorrow.Uh, his name is Ross. He was an early investor and also a kind of co-developer of Sheba. So he's someone that I think I can say confidently knows more about Shiba Inu than 99.9% of people in the world. Um, so if you're interested in Sheba or what's next for the coin tune in tomorrow, he'll be on about one 30, uh, Spencer, any thoughts on this crypto heat map?I I'm trying to get a link right now because we're actually doing a sheep giveaway. I'm trying to get the link for that. I don't have it handy, but we're giving away some free shipping. I hope somebody gets me that link so I can get it to you. Uh, that's my thought, my thought is no. I mean, Bitcoin is an inflation hit crypto isn't inflation, hedge.Um, I don't quite understand the why it's down like this today, but you don't. All you need to do is look at the reaction to Bitcoin at 8:30 AM. Eastern time yesterday, right? Inflation comes out. It's harder than expected. It's it's more than expected. What does Bitcoin do? It goes up. Mike is saying, Hey, be it.It's a good play. Definitely go for PayPal options. Um, so I don't know if he's, you know, facetiously saying that he wants to see me lose some money, but I'm looking at him. I'm looking at the calls. Um, but yeah, Spencer, like you mentioned get some free Bitcoin we'll we'll throw that zing token up real quick.Go to Voyager. You put in a hundred dollars, you get $50 free Bitcoin, if you use the code zing. Uh, so not a bad deal at all. I mean, who doesn't want $50 of free Bitcoin checkout Voyager for that? Use the code zing. Um, all right. Real quick before we get to Ben. Yeah. Yeah. And, and I'm going to post the link to the ship giveaway.Um, when I, once you find that I find it. Yeah, no problem. Somewhere out there, easy Mick, you might be the guy who knows technicals what they're talking about when it comes to technicals, I'm watching a. Dash, which has been up a lot over the past, I don't know, week or so. Is this, is this, this the kind of subtle head and shoulders forming on the, on the one day chart?I think we're looking at five minute candles right here. I see one shoulder here. This could be the head, if this is the, the second shoulder, um, you know, could it start falling down or should I be looking at some dash puts, I need someone who knows technicals better than I do to let me know if this is, uh, you know, I'm not a big patterns guy, so I'm not really know, but we have some people out there that are outsourcing.And I know, I know when I need to listen to someone that knows more than I do. Yeah. Um, Alvin say, and he's looking at Wayfair puts an ADSL. K what's ADSL desk. Autodesk. Yeah, by the way, I just put the link in the chat for the ship giveaway. There it is. There it is. You can't click it on the screen, but it's in the chat.I'm just throwing up there. So y'all know it is there. All right. Y'all so story train. If you guys have watched a show before you've seen Ben on the show, he gave us a E H R at, I don't know, four bucks, three bucks. What does it now? It's like, I like 20 let's check real quick before he comes on. He'll give us an update on AHR.Um, it's at $23. So let's see. I mean, it's, it's up. I want to say like at least 200% since he pitched us to us on the show, he's got a couple more stocks. We're going to talk about, uh, Should we bring them on easy MC RSI? Isn't it. If the RSA is 90, isn't that a sign it could come to? I don't know. You, you know, more about technicals than I do.Let me know. All right. Without further ado, let's go ahead and get BenOh, Ben, what was the, what was the price of AHR when you first came on the calendar? What's up guys? Yeah. When I first came on, the show was around $5, five 40, somewhere that somewhere in the low fives, I believe it was. Yeah. And when we first presented it to our VIP community, when I presented as a trade idea, it was $2 and 74 cents.What, all the way up to 27. So it was a 10 bagger if you captured that. And I happened to pretty much captured that I was done. I'm handing this from 2 74. I didn't sell my first shares until 16. And then, um, I sold a lot more in the, in the 20 to 25, 26 weeks and maybe even gotten a little bit at 27. So, um, yeah, I've got a few updates for you on, on that.And a couple other sucks. Yeah. You got a new background. This is the first time we're seeing this. It looks pretty good. Yeah. A lot more work to do. We got to get that our mikes and cameras and everything, but yeah, this is the first time anyone's seen this background. Cool. And you said too, it looks like we did.It took us far too long, but we eventually got it together. You get a zoom out so Ben can see our beautiful. Oh, wow. That's great, man. Um, all right, Ben, you want to go ahead and get your screen shared and we can go ahead and run through those slides real quick. I know we only got about 10 minutes, so we've got a few I'll work.I'll be fast. All right, there we go. All right. So yeah, first we got that quick disclaimer, we got to always do that. A story is not investment advisor and missing his spirit is in most gimmick where some losses of you who are new to store trading, what is associate is the practice of understanding market pricing.We also call that the story behind the trade through the four pillars, which we say are sentiment catalyst, fundamentals, and technicals. That allows us to take a holistic look at markets and make choices based on all of these factors, not just one of them. So air story, trade idea, update. I officially opened that in my community on July 8th of 2 74, I did close it on November 8th of 25, 79.I still own some shares. Uh, I ended up selling about nine giving 95% of my shares. Um, Monday morning was really the trigger for me and that's because I saw something, the technicals and also the sentiment, which caused me to say, let me, let me lock in these games. And the technicals last Friday was the.Solid green candle on the chart, you can go look it up the first solid green channel and then tire run-up, which, which means it started the day high and then went down lower throughout the day. And throughout this entire run, it was starting low and going higher throughout the day. I took that to be a reversal sign plus the sentiment, I think when reached peak Eby sentiment for now, for this cycle with, uh, Elon Musk selling shares of Tesla with the Caribbean IPO, with excitement, but Eby infrastructure.I'm trying to time that sentiment top. So I took my profits. I am keeping about 5% of my shares because it could go much higher still if they get the right contracts in the future. Got it. Um, so it took some money off the table, trim some of your position and air took those profits, never a bad move. Uh, Ben, what else?I was on your radar today. I wanted to give you an update on side, cause I was on your show. July 26, we presented this at $5 and 70 cents. Uh, this is stuff that's been up 66% since it was initiated in our community. At the time we said, Hey, T-Mobile's come in. End of month in August. It didn't happen then.But it happened last night. Uh, so a few updates. They have earnings last year. Um, so this T-Mobile deal came three months late, but it's finally here. Now, key, this was announced last night on the conference call only. There's no PR yet. So people who are in the know who are listening to the conference call, they have a big edge getting into the stock right now.Um, there probably will be a PR at some point in the future, and there's also tremendous traction with their other customers, 18 T and Verizon. Um, there was an upgrade today to $9 and I'm not even sure that Benzinga caught it, that upgrade by the analyst and $9 by lake street. But we think in our community, it can go much higher.Uh, there's uh, estimates out there in our community saying we can do go up to a dollar 33 DPS by 2024, which would be a $40 price target. So that's the update on SSI. You know, our investigative research worked and we're read about T-Mobile just a few months late. So this company is going to start printing lots of tests going to be a very profitable company.Do, do you have a target? Um, yeah, no, I don't have to stop losses. God forbid men. No, I do stories yet. I never do stop losses. So I've been holding the stock for like two or three years. I increase in decrease my position around catalysts. So, um, I was buying and after hours last night I bought a lot more today.It's now my largest position actually. And uh, I'm not going to put a price target. I see how it goes. I, I assess the fundamental sets of metallics and technicals on an ongoing basis to determine. There you have it. Yep. So I do have a new pig that I'll get to in a second. But before that, just a little quick alert, maybe something for you guys to look into and talk about, because this is a big kind of big cap for us.At $1.5 billion company GoPro. We presented it to our community Sunday night, um, because the fundamentals are super strong. They had earnings last Friday and we have anticipated a technical breakout of the 200 DMA, which just happened this morning. And this is really, it could be a really fun situation, wanted to bring your attention because it has, this has short and gamble, squeeze potential, very high, short position.He has sense of it has been very, very low, but the financials have completely turned around with this company and they're printing tons of cash. Now you see the technicals broke. The options are very liquid, very cheap. And if it gets into the right hands and the Reddit community, et cetera, this could be a crazy profit potential, you know, with shorten game of squeezes.So keep your eye on that. But go. So GoPro's up about 9% today on the strong earnings. Um, so I, I mean, I, I don't know, personally, Ben, if I'm going to go in and try to chase GoPro and it's already up 10%, but I, or 9% today, but I definitely like having it on my radar. Uh, J rice in the chat was also talking about GoPro saying that he thinks it could be a long-term turnaround play.Uh, I don't know. Munis has been one of those stocks that has just been like beaten down over time historically. Um, but you know, at some point I don't think you can ignore the fundamentals or Fridays when I got in added more Monday, uh, I got a little bit messed up on the options than playing the options.So I actually lost some money. Cause I got scared with the whole inflation thing yesterday, but I'm in it now and yeah, the sense of it's sport, that's the only thing people hate this company, but they're printing cash like crazy. The technicals are turning and shorting, given squeeze potential, such that this, yeah, my all hold back a GoPro has always been that.I feel like they have a very limited, uh, customer base, you know, it's like who, who who's going out and buying GoPros. It's people that take part in extreme sports, you know, mountain bikers, snowboarders, skiers, et cetera, outside of that. Um, I don't, I don't know how many, you know, everyday people are GoPro customers.It's absolutely correct. And I'm not, you know, I wouldn't take issue with that, but the amount of earnings they have like 60 million EBITDA this last quarter. And if you compare it with their market cap, I mean, this thing can easily be 17 bucks. Even with that knock against it. Got it. Um, I been, what else is on the radar?I have a presence. It's my first story. Trade ideas. Since air. I presented this to my VIP community last week. Okay. Listen to the presentation. Don't just jump into buying guys. Okay. Because of what happened with their, every stocks, not air, I can guarantee you, this is not going to go a thousand percent in the next three months, like heritage.Okay. So that sock is Gaia, ticker symbol, G a I a. All right. So we're going to look at it and yeah, it's a smaller company on the ground, 200 million market cap or so, but you know, what's the story behind the trade. That's what we're trying to figure out. And again, we look at the sentiment, the fundamentals, catalyst and technical.So let's start with the fundamentals guys, digital video subscription service, like in some ways like, like Netflix, they sell, um, they make original content for yoga, alternative health, holistic healing, nutrition. It's a monthly subscription service. They've been growing steadily over the last many quarters.They're profitable. Uh, fundamentally I think their inflection really happened to a quarter or two ago when they became profitable. And you can see some of the, uh, the trends here in terms of their, um, their revenue and their EPS, although in the right direction. So in our community, we collaborate with people who are really steeped in fundamentals, just charts, courtesy of Mark Holmes.He has a risk reward chart here in terms of what is the value of this stock and. You know, it's worth, it could be worth at least $17 a share. And the stock is very cheap here. So, so that's the fundamentals. You can check it out on your own. Go look at the earnings report and you'll be able to verify everything I'm saying about, uh, the growth and the subscriber growth and money they're making written it now.And it could potentially be, uh, you know, Netflix may buy them out one day. You know, there's, there's a lot of opportunities here. So, um, yeah, catalyst let's go to the next pillar. Uh, in these sorts trading four pillars, they had their earnings just recently, November 1st, it was 20, 20, 20 2% revenue growth, uh, year to date compared to last year Q3 EBITDA of $4 million.Uh, even a margin of 20% was their fifth straight quarter positive earnings in cashflow. Um, and then they had an additional catalyst the next day. So we'll talk about that catalyst in just a second. What happened the day after earnings, but first let's go to sentiment. So the sentiment is kind of poor with the stock because fundamental investors are frustrated at the price action.I know a lot of fundamental investors saying this should be worth 17, 20, 25 bucks. Why is it $10? Why is it moving yet? So I listened to other participants. I say, I talked to people in social media. I talked to people in my community. Why aren't you interested in the stock? And this is what I'm hearing.The total adjustable market may be too small. It may be too niche, their content. We talked about alternative medicine, yoga, meditation, and things like that. So it feels like I'm just not interested. It doesn't seem like a huge part. Other people say, Hey, the content, they have some content that's kind of fringe on their French content.Like some of that alternative medicine, there might be some videos on, you know, some vaccine hesitancy type stuff or who knows, like some things are it's alternative content, right? So some ESG, uh, buyers, uh, may stay away from that environmental social governance. So that's another knock on the sentiment.The other knock is this is just slow and steady growth it's and where's the hockey stick potential on that. So just remember, this is the poor sentiment. This is what happened. Going back to the catalyst the next day after earnings, after we know the fundamentals are great, the next day another catalyst hit the other, the catalyst was there was a PR that Demi Lovato became a brand ambassador for.And there was a press release that a lot of people didn't see a where Demi Lovato says I'm excited to be one of Dias. First celebrity ambassadors, and honor to join a platform. I've been a fan of for some time she has 118 million followers on Instagram. And the market cap is again like 189 million. So this company has been growing slow and steady.And all of a sudden, they hit you with this news of Demi Lovato is a huge mainstream personality, that and company, I want to go back to this. Airpoints the one thing I saw that the thing about Demi Lovato, uh, in, and I, I guess I didn't realize this was the same company, but like they got a lot of weird shit on their platform.And that was the sentiment I was talking to. They're saying, oh, there's stuff is weird. I just don't want to own this company. But you know, I think that, you know, they're growing steadily, they're getting to a place where they can really focus on growth now, and to me, and let me go back to that bad point.You just made that pinpoint. You brought it up for me, right? Yeah. They have weird stuff. It's too niche. The French content. They keep some buyers away. But this is where I think that Demi Lovato news is really significant because they're in a financial position now to really grow the company. And to me, this signals.And in fact, in that PR said, I'm excited to be one of guys. First celebrity ambassador, And I have a feeling this company is going to start growing their content and start getting into more mainstream content. And based on what you're saying, I think they may be looking for more celebrity ambassadors.And it's just a great situation because the downside is so limited. You have a fundamental floor here and now you have optionality upside. If the company starts doing things to get that hockey stick growth potential. And that's why I really add it to my position here. And I'm very excited for the next several months on this stuff.Um, let me just go to the last or technical resulted with her awesome technician Rex. And this is a monthly chart is saying, uh, this can go to the twelves if it breaks out of the yellow.here, which thought is that shorter than I think the current breakout circled right there. It's got a breakout of, I guess, 10 70 area.He thinks it can go to 12 for the month. And here's another view which looks much more bullish. This is a long view of the monthly chart is a sometime in the future. When the 12 to 13 breakout at the blue line, it should proceed to break out the all-time trend at the white line. And he thinks this is a several month play for that to happen, but you can kind of see where this can go.Uh, if that happens. Uh, any questions on that or any of the other stops, man? I didn't see this one coming. I didn't realize this. I read about this company and I was like, man, I didn't even realize they were a public company until you came on here. So, um, I'm all I'm putting two and two together here. Uh, Ben, thank you as always for coming on the show, we appreciate it and uh, and have a good rest of your day.Please follow us on YouTube. Thank you guys. Thanks a lot, Dan. We got to get moving. We got our next guest. She's already here. We're going to talk biotech guys. I know that we, we always get asked. We always get questions like when's Vivian. When's Vivian. When well she's on right now. Not right now. She'll be on in like five seconds when we bring her on.But Vivi Bio-Queen will be joining us every Thursday. At this time, I told you all to save your questions for your bites. The questions for right now, let's bring her on Vivi. How are we doing today? Good. How are you guys? Can you hear me? Well, we hear you. We see you and we have questions. Oh, awesome. And before we do any questions, I think, um, we can do some updates.I did have a request on Twitter to cover it stock. Um, like at my old good lawyer friend, mellow at Twitter, I, this is out for entertainment purposes. So, uh, is only my opinions are for entertainment, purpose, not a financial advice. So I wanted to, uh, first of all, um, talk to you guys, um, just given up a date, we just had the, uh, ER, on KMP.H can you guys put that up over there? Yeah, this is a daily chart. Okay. And P Hit's quiet. So, yeah, so we just had the ER and I want to, so when I, when everybody kept asking me, like, what do you, what are you going to do for 'em? What are you going to do for K MPH? My position was this small because he is a, some of the concerns I had. I spoke to the manager and he interviewed me. And, uh, he said, you know, we're not going to put any reps in New York yet.And it's just going to be certain regions in the United States. And for me, it showed a little bit of a weakness because for me, if you launching a drug, you should have put reps all over the map. But I think they're just trying to be cautious. So they report around like, I think 2 million in revenue, but here's what I'm bullish.Now. They just launched the rest of the Salesforce. And this company here, you know, their burn rate is really, really small because Korean is doing all the selling. So the burn rates is like a million a quarter and they have a, still have 135 million. And he is what I'm bullish of. Um, there's a company that sells a scripts and there's a guy that, uh, his friend works for this company and feeds him all the script.So for you guys to have an idea, right, the, the feedback has been amazing. So July, they had a nine scripts for the monthly and then August, they had 173 scripts, um, September 416, October 886, still low because there were not out throughout the nation. But I think the feedback has been tremendous from psychiatrist, from the drug and the differentiator.And I feel like as they deploy, uh, the other sales reps, we going to just ramp up the sales. So I feel like at this moment, I wanted to add a little bit more to my position because I, I see the future being very bright here, KMBH. And I think that, um, we gotnot yet. Not yet. I, I should have now I have an, I am waiting for some of my swings to flourish, so I haven't been able to, to add, but I wanted to for sure. Okay. And then I want it to put you guys out. Somebody asking me to, uh, to, uh, cover a, uh, a N N S. Hmm. Okay. Now I want I'm familiar with, but it is biotech.So it's a biotech it's under the radar. So I wanted to explain to you guys some of the reasons how I invest in biotech, and I told you guys, if there's no commercial products, there's, there's got the most important thing you can look at is cash, right? Because if you don't have a cash, no product, are they going to burn too much?And they also gonna have a, to do offerings. And if the stock is low, they do reverse the split. So the first thing I do is to look what was the cash burn and how much cash they have left in a would the future and what the catalysts are going to be. So this company here, the first thing that got me to, to look at it was they have a $271 million in cash.So they're really the city really strong. So I thought that was a really, really, uh, um, uh, valid, uh, information, very important. Then I look at a financial institution on. EVestment, which is a goblin, was the director of FDA is a partner on their firm. So they own 2.5 million shares. So I thought that was another very important information because goblet is well connected to FDA.Not that you know, it nobody's going to be bought out, but when you have investors that work with FDA, they know what it takes to, to be compliant, to get a drug approved, right. Because it's just so much behind to get a drug approved. So manufacturing, you know, how the studies are designed. So I like the fact that there's Nia investment behind.And then I also know VOD is, oh, 2.1 million. So Novartis has some interested and, and the pipeline, it looks really, really amazing is all CNS, um, uh, and mass. Um, they're going to have, uh, Gilliam Barre syndrome, which is a very rare disease. So I really like this company. I really do. I, I'm not, uh, obviously I can't be in every single stock.Uh, but I, I, I, I think this is a really good a long-term, uh, stock to hold for sure. So that would be one. And then if you can, um, bring back, uh, pro GPRO G we have a lot of fans PRG. It's like almost like a min stock, but also a really good stock to hold long and, um, really. Yes. Yes. So, so what, what do you see that the market doesn't see, um, what I see that the market doesn't see.Um, I will tell you why this company is going to be huge. They have a two types of, of delivery system. They have a, um, on, I'll tell you guys, they have a two to two technologies and I wanted to bring to you guys, let me see. I can share a screen. Okay. But I have it here right in front of me. So they have two things.They have the OBDs okay. Which is oral Biotherapeutics delivery system. So what it does is, is able to take big formulations and put in a form of a pill. So for example, Humira is one of the biggest blockbuster drugs in the world. If they found a $10 billion. So you imagine if Abby, I think Abby is a Humira honor.If, imagine if Humira is loses patterns and five years, right. And all of a sudden, because doctors love the efficacy of this drug, and that's why it's so well prescribed. Right? But it's an injection. Imagine for this company sell their technology. And all of a sudden you can have a drug, like a Humira being, um, given orally, all of a sudden you create a whole new patent for that drug.Do you follow me? Because a different formulation. So all of a sudden you gaining another 15, 20 years. I have a patent on that drug. Now imagine how many pharmaceutical companies would have be jumping all over because they like, geez, I have this, this drug that's high formulation. And now I have a, I would love this drug to be an oral form because patients do prefer to be an oral form.So I see, um, they announced that they have three partnerships with the big pharma, but they have announced who, so everyone is kind of on a suspense, like who are going to be the big pharma. So they have, uh, right now with the Pfizer there, just to have an idea, they, the not only the delivery, the delivery system does this to the big formulation, but also one of the drugs of four in any boat to the second one, the oral bio biotherapeutic delivery system.The OBDs, what it does is it's designed it to, to, um, to take it a pill and the pill, the way this delivers it, doesn't go all over your bloodstream. So it's it's for the GI tract. So is GI specific drugs and there's one. For for, for, uh, uh, Pfizer they're there. The preclinical, what they found was not only that, that would their delivery system, that drug was 25 times more potent than the Pfizer drug, but had a no toxicity because it doesn't go to the bloodstream.Like the other drugs would go. So you have a less toxicity, less, less side effects. So imagine what they can do if they already doing this with Pfizer drug, they're studying the Humira. Imagine like for me, this drug should have just literally like get royalties for every farmer, choose the technology instead of it being bought out.Right? So I believe this, the future of this company is super, super bright. Uh, you know, it's heavily shorted. So I think that a lot of people are here for the, the, the, the gum is squeezed because if you look at the amount of, of, uh, of, uh, options, that the options chain is crazy, uh, for this, for this company.But I, I will, like, I have a big position because I wanted to, you know, to trade around my core, but it's some, it's a company that I wanted to keep it. And, um, and a long term, uh, option, because I feel this company is going to be huge. So they just appointed also geo hall, believe it or not do, how do you, how, um, she's in a board of directors and this woman, it's like a powerhouse in biotech, a friend of my work.As so maximum, so messenger gas sold. So she comes in with a lot of experience in pharma and a lot experience in acquisition. So, uh, the team is fabulous. They are four miles away from my house. I should have just bring them a bottle of champagne when we hit $10. But I believe in this company, this company has a bright future and that, um, right now there's a lot of people on it, you know, waiting for that short squeeze.But, uh, it's been keeping really it's being holding like it dipped to, to like 2, 3 0 3 today and it went right back up. So it's been keeping, you know, I think the short sellers were expecting after der cause you know, there's, you know, a yard for a state, uh, initial stages of biotech doesn't produce revenues.Right? So it, it dipped to fund 360 2 all the way to three, but it's been holding for weeks at that average. So people are not selling people believe in this company for sure. Uh, can I ask you, what do you, what do you get, do you have any favorites in the, in the gene therapy space? I do. I, um, I, uh, I, I'm a loan holder for ADP and they have the, uh, it's one of the car T therapies, but it's not the car T is the RTC, uh, ADP.And, uh, the reason I like this company is, uh, not only they have a partnership with Genentech, uh, the Genentech partnership is up to three. And, uh, they already have enough funny from Genentech cause they got, they gave them a prompt payment payment. They have funded into 2024. So I feel like this is a very safe play in regards to not having offerings and that they are sitting with 285 million in the bank and they do have, uh, some, um, some, uh, catalyst coming.And, uh, I, I believe this company will be a multibagger on day, you know? Uh, so it's one of those that you set and forget it, but I like the position of cash because it gives me the comfort that they're not going to be throwing in offerings after a big catalyst. You know, they, they have they're in a really strong position.And when you look at, uh, um, institutional ownership matrix, all 15 million shares of this company, baker brothers owned 18 million, the institutional ownership. It's so strong in this company. And obviously Jen at that has a huge, huge portion of the company and has their eyes on the company. So, uh, this, this is a big one for me.I got to ask you about, about BCR X here. That's the rule. Every week we got to talk about BCR ex of course, it's this year access to my unicorn. You guys, for sure. So, um, it's, it's funny. I held this space as on Twitter yesterday, and I was talking to a pharm D you know, I do respect, they have a lot more knowledge than me, you know, uh, in terms of a clinical.And he validates my position on the CRX and GRTs, which is great stone. And he says to me, you know, be CRX is, is a rare diseases monster in the making. So they, um, they just released the earnings. They put 38 million for the quarter, and people, BU people were really upset that it wasn't 7 million like this huge numbers, but for the mentally long-term, it's still there, right.Because the science hasn't changed. So I see this as an amazing opportunity, uh, if you're not in the CRX, but, uh, just, you guys have an idea. Uh, the biggest drug for, um, for Alex yawn is, uh, Alto Morris. And they are not even that good because it's not only an infusions for PNH, but patients still need transfusion, uh, taking this infusion every eight weeks.Uh, BCRA X has the competitor, which is going to be an oral oral, uh, competitor factor D and not only patients that have been on this study up to now, not only they jumped from phase one to phase three, because they did so. Patients to this date. I think there's 40 weeks, 30 weeks of, could it be this fusion to this date?So imagine having a drug that is, it's already a rare disease for PNH and patients only at the choice on the available is in Jackie, no infusions. And you still have to go through the transfusions. Imagine having an oral pill that you don't have to have a transfusion at all. So just make them do the math and Alex, the on 70% of its revenue, 70 was on PNH for this drug and they got bought out for $39 billion that would have put the CRX at a $230 a share.And B CRX has a better pipeline with a more potential and it's going to be all oral. So you guys do the math, if you don't think this is a monster in the making. Alright, Vivi the bio queen, she joins his every single Thursday at biotech. Underscore SD is for Twitter handle it's up on the screen. And uh, and then please.Yeah, please, if you, I will post my DD there because this is a very short, so you guys searched the bioclean on Twitter and you can find me all right. Thanks a lot. Viva, talk to you again next week, next week. All right. Uh, Hey, let's stick with biotech for a second here because our next guest is the CEO of a gene editor.Company, hence why I asked to VV about that one to get her thoughts. So, uh, if we can, let's go ahead and, uh, and, and, uh, bring her on guys. Andy Ford. She's the president CEO of Mira GTX. His company is a lot going on right now. They're at a very critical point. So let's get Zandy onum, Ford,by the way. Yes. Thank you. Thank you. Where we're actually, it's on our to-do list to get new music, but, um, thank you for, for, for the compliment. Uh, so as I said, it's a pretty critical time for, for mirror DGX. Uh, you guys just presented at, uh, uh, the virtual, uh, oh gosh, uh, the European society of gene and cell therapy Congress, right?Uh, yes, we did add three abstracts. Yes. Right. And then there's a, we're due for another, a little bit surprised when I found out you're on the calendar. Cause I thought you guys, you have another, uh, presentation coming up in a few weeks. I, I, I think I believe right. We do. So we have, um, quite a number of presentations in the second half of this year, uh, which included, uh, some presentations at the meeting.You just mentioned on our programs and our switch that allows you to switch gene therapies on and off with a pale. Um, related to what video was just talking about, actually, that's what I do want to talk about. I'm sorry about, and then, uh, at the beginning of December, we, uh, having a clinical update on our xerostomia program for patients who've been cured of had a neck cancer, but don't make saliva.So we'll be completing that study this year and we'll be updating on the clinical progress so far at the beginning of December. And then a couple of weeks later in mid December, we're having a science day to discuss in some more detail, uh, Ribas switch technology and our promoter platforms, which allow us to really optimize gene therapy.And for the first time switched gene therapies on and off with an oral drug and not just switched them on and off, but quite precisely dose the amount of gene therapy at a particular time with a dose of an oral pill. So let's talk about the switching via via pill. Yes, exactly how that. So obviously gene therapies are a virus which contain a gene and there's a coding sequence of the gene, which will make your protein, whether it's Epogen for example, or whatever, uh, gene therapy, it might be RPG or for the eye.And that gene is activated by a promoter, a regulatory sequence at the beginning of the gene. So that's the normal gene therapy promoter and a gene, the promoter switches the gene on, and it remains on for the rest of that patient's life, all that sells life. So you have persistently expressed gene therapy, but what we've been able to do for the first time is we do everything.I've just told you with the promoter that regulates the gene therapy and switches it on. But on top of that, we put into the gene sequence, a small sequence of DNA, which instructs the entire RNA produced from that gene to degrade. However, if we give a small molecule, but via pill, and we've got many small molecules, because we've developed this as a platform, it stops that degradation.It cuts the entire degrading sequence out of the gene. Produced RNA and you'd get the gene switched on as if it was never there. So for the first time we can deliver gene therapies, which are not on, so they're not producing weird proteins or bits of proteins. And we give a pill and bomb that I'll call it.The degrading signal is cut out of the RNA and you get a perfectly normal protein product.I guess I have so many questions. I don't even know where to, I like that all sounds incredibly complicated. Um, I guess, uh, how can you make sure that it works? So it's, we've when we set up the company, this was one of the technologies that we, um, we wanted to build and these switches made of RNA shape.There are thousands of them and bacteria. And for, for decades, people have tried to take bacterial switches and make them work in human cells. And rather than doing that, which hasn't worked very well. We built, we use the theory of Reiber switches and we built based by base our own switch. So we built it in mammalian cells.We then tested many switches and we have a platform of switches we can control. We were able to make these really simple switches, which switched on and off to high dynamic range. So 5,000 fold above the off level when they're switched on. And as a consequence of that, we were then able to change the drug that we activated with.So now we have multiple genes that we've put our switches in sitting in our freezers. So, uh, various antibody, PCSK nine antibody. You'll be aware of, uh, PD, one antibody, the, the very large drugs we can regulate. And then other drugs like GLP one, obviously a diabetes and obesity drug, which we can regulate.So we've got those genes and we can now put them into vivo in mice and NH PS, and we give those animals small molecules and we've already shown. Based specifically on the dose of the small molecule, we see our drug switched on to exactly the right level in each animal, depending on the dose of the small molecule you give.So we have built this over the last five years and we have moved from cells to mice, to non-human primates. And we're currently in a position to start doing I N I N D enabling studies for both the small molecule, all drugs and the genes that they regulate. Uh, and then as far as use cases, I know you're working on, um, you know, you're working on applying this, um, to, uh, I disorders, right.Uh, but is that the only use case right now? Tell us about the other one. No. So, um, we developed this technology of controlling gene therapy with a pill in order to much more broadly open up the space that gene therapy could be used in. So. We do have a lot of expertise in the eye and a partnership with Johnson and Johnson for our rare eye disease programs, but in diseases like wet AMD or dry AMD or uveitis, those large diseases.These are targets for regulation with our cassette and small molecules. In the case of our wet AMD program, we inhibit VEGF like other companies do. But what we're able to do potentially is when we put that gene that blockades by Jeff into the eye, we can formulate one of our small molecules. That's otherwise oral into eyedrops.So what we're working on now is turning our small molecules into eyedrops. So we can put a wet AMD drug or uveitis drug into the eye as a gene and switch it on each day with an eyedrop. So the eye is an excellent place to be able to regulate gene therapy with a small molecule, another place, which is really important is in the brain because it's very difficult to get antibodies or biologics across the blood-brain barrier.But what we're able to do potentially is we have regulated antibodies and we can put the. By an injection into the brain, just a one-time injection within the blood brain barrier. And then all you need is a pill which crosses the blood brain barrier. So it allows us to deliver drugs that really hard to deliver by other routes.And there are many, many more applications. It, it hugely expands what you can use gene therapy for, because for the first time you can control how much you gave. And at what time, uh, it seems like broadly speaking Zandy, um, gene therapy, like what, like as an investment, it was like super sexy a couple of years ago.Right. And then it sort of, it was super hot and then came down a little bit and was like, oh, wait a minute. This is still really days. Where, where are we now? Are we like back to, is gene therapy being like the hot, the hottest topic in biotech? Or, or are we still sort of, is it like the off cycle? I dunno how else to phrase it?W well, I think there are, there are many different gene therapy companies and there is cell therapy companies. There are very, very large number of, of, uh, therapies in the genetic medicine space. And, um, and there are some companies that just have a product or a platform or a particular organ that they focus on and that.Is a somewhat higher risk to those companies that depend on data around a particular study, right? What is quite different about mirror is that we established the company to really innovate in gene therapy and shows indications in the clinic that had good proof of concept and highly likely to work and to support a future pipeline.We built everything you need to be a gene therapy company in-house so we have multiple promoter platforms, multiple capsid discovery efforts. We have our own internal manufacturing, which is probably the broadest engine therapy today in that we manufacture our own GMP plasmid. We have two, uh, viral vector manufacturing facilities, which are flexible and scalable to commercial scale.And we do our own QC and analytics as well as potency assays. So we have a very, very broad, I suppose, toolkit that's required for anything. That you need to do in gene therapy and went out, positioned with this regulation ability with a deep pipeline of regulated genes that we can then take through to the clinic with our vector ecology and our own GMP manufacturing,not of the regulatory by putting all that in house. I was just gonna ask, as, as we get more developed in this space, like Spencer said, it seems like a couple of years ago, you know, that the gene editing space was huge for investors. Uh, what advice would you give investors that are looking at different, uh, you know, genomics companies to, to be able to discern which ones are going to have an advantage in the, in the field once the industry does become more hot among investors?Again, I do think that right now, manufacturing is not just a bottleneck with respect to capacity, but, um, Dealing with regulatory agencies globally and an expertise in manufacturing process. And, uh, and the assets required to show the release and stability of your products is very, very important. And to be able to either have that, to have as much of that as possible in house dearest clinical programs that you'll see, particularly if you have those sorts of capabilities at the time of D you really don't want to see companies that are starting manufacturing their product in one way.And then at phase two, switched to another way and then have to scale it later. Ideally, you would look for companies that have capabilities that allow them not to necessarily rely on CRS for plasmid manufacturing or in DQC. And we learned that over the last five years, it's one of the reasons we've bought, uh, so many of these capabilities in house, but I do think that's very important.Um, in addition to obviously, you know, do the targets work or is this, is this an appropriate, um, disease for gene therapy, the nuts and bolts of being able to produce and show the agencies that you've produced the right thing, a really important. Zanni Forbes is the presidency of Mira GTX. As I mentioned, there's a lot going on.You guys also got some positive in Canberrans over the weekend and, uh, uh, a lot of presentations after being in stealth mode for quite some time. So, uh, looking forward to seeing how things develop here and, uh, and, and, and good luck going forward. Thanks a lot for coming on today. Thank you so much. All right.Hey, w we got to keep the train running on time here. We've got so many guests today, back to back to back to back let's pivot. If we can, maybe we just spent the last half hour or so talking biotech, uh, let's pivot to like supply chain, specifically, uh, supply chain of textiles, right fashion. And what exactly is going on there?What to find out? We're going to bring on our next guest here in just a second and running Samuel. He is the CEO of a cornea technology, and, uh, let's bring coordinates and a Ronan. W that's been running on this show. Now, if we can guys, I guess I'm Spencer, I guess I'm doing that. All right. I got you right.There you go. Good morning for us this afternoon for you it's later on in the evening. So I appreciate you, uh, coming on, uh, the, the, uh, the show here today. So, uh, let's talk about textile supply chains, right? Uh, what exactly is going on there right now are things as bad there as they are in other areas of the.Well, um, yeah, it's bad. And it has to change the supply chain is broken, but even more than that textile industry and fashion industry in particular is the second most polluted industry in the world. Um, from different reasons. One of the reason is that 30% of whatever put use on textile is actually never been sought.Uh, and this create a huge amount of waste, both of materials and water, and we have to save the world. Um, uh, so we have to change the industry. Now, the reason for that is some of it is because the supply chain of today doesn't meet or doesn't fit the need of the consumer of today. The supply chain of the textile industry is like centuries ago, you produce in large quantities in forest, in China, in Magilla dish, you trying to forecast what the consumer, what the people would like to buy a year in advance, sometimes 18 months in advance, which is impossible.It's crazy to think that you can predict what the consumer today would like to wear in a year and a half from now. So we have to change it. The world move to digital in many, many industries. And in this industry is still fully. Yeah, I'm glad you brought up the, uh, you know, the environmental impact of the textile industry, because that's something that's gained a lot of attention over the past year or so.I mean, you have a quote unquote fast fashion companies, such as sheen and people have kind of started attacking the, the idea that, oh, buying, you know, a cheap t-shirt for $15 or some pants for $15 that you see an ad for an Instagram, uh, causes a lot of environmental distress. So what do you think needs to be done in the industry to address that?So they, this would need to change in order to try to predict what the consumer would like to buy and put, use Lauder moms of products, which will never been sold is to produce, to demand, to produce after the consumer.But that's not efficient. I mean, it you're saying it is, but that's not a necessarily inefficient use of capital though, right? No, no. It's, it's actually a very, very efficient, um, hold on, explain to me, explain to me, yeah, let's begin with, first of all, what we see that production is really moving on shore.Why it's moving on shore, not only because the, the, the supply chain is broken because you have to be closer to the consumer. You have to react fast for the consumer trends. Now, the world of fashion and textile move is moving online today. 30% of all purchases being done online. So e-commerce the focus by 2025, that it will be more than 60%.Now, the online the e-commerce of today is still trying to sell you what they have in the inventory or what they have in the shops, in the stores. Uh, and if you going to order products, sometimes it does not exist at all. Um, and uh, sometimes, um, for the brands is really, really difficult to. Okay. Can you hear me okay?Yeah, we, we, you we're fine. We just got disconnected, but we're back. Okay. So, so I missed everything you just said. Okay. Okay. So let me try to explain again. So the world is moving digital. What does it mean? The consumer today's buying? So e-commerce online. 30% of all sales is being done online and the focus by 2025, that it will be 60%, but the online is today's actually a mirror of the store.Doesn't allow you to choose your product. They're trying to sell you what they have in inventory, which doesn't fit what this consumer would like, what we believe needs to be done, that the online should be filterable. You shouldn't have any real physical products. You can have endless amount of product virtually and connect the virtual wall to the physical world.And this is exactly what committee's doing is enabling on demand, production. You order what you want only. Then you produce it. You produce it close to the consumer. Onshore and delivering, you know, the same day on the next day to the consumer, the product, I feel like this is I'm in now. It sounds great. I think that, but that's like, that's more difficult, right?Well, I give it a few examples. Well, one example, great example. Thinking about the books book markets, um, back at 25 years ago was fully analog. You went to a bookshop, you tried to buy a book. You only have them, the shelf, the books that we're selling in millions of copies, Amazon disrupt this market. They created a digital world.You could go to Amazon buy any type of book, even from 200 years ago. But what they create is actually much more, the impact was much more than that because now everybody can become a writer. You can write a book about your family, about cooking, about anything you like, you publish it. Virtually doesn't cost you anything.Only when someone is ordering, then you print it and send it to the consumer. So the same thing is happening now in the fashion world, you don't need to have it physically. You actually unleashing creativity because you can have endless creativity and each one of the consumer can choose whatever they want in any Colleen, any design.And once you choose it only, then you produce. So this is efficient and there is no way. And you produce it using coordinate technology, which is a fully sustainable green technology. That was my next question was just if you to clarify that, so I come up here like Amazon, for example, uh, could have used your technology, right.Or, or any retailer, right? Could just buy your technology and, and use that along their supply chain to make it more and more green, more efficient. Right? Actually, Amazon is our biggest customers. Okay. Amazon is our biggest customer, but we have many, many more customer. We are worth more than 1000, 300 customers that using our technology all over the world.Some of them very big companies like Amazon, like Adidas, like fanatics, but using our technology. And you can go online and order products and customize the product and order your t-shirt here. You can see with coordinate on top of that or on any color, any size, any shape. And this is the new world. Look what the world is moving into.What is moving into metaverse. So metaverse is everything is virtual. You will have. Your image in the metaverse. Yeah. You will be able to dress it as you wish with any, any type of, of, of goods. Uh, and only when you feel that you lack it, then you order it and then it would connect it to the physical world, which will be big produce next to you.If you are in New York, it will produce in New York. If you are in Beijing, will be produced in Virgin and shipped to you the same day. So the impact on the environment in terms of sustainability is huge and their efficiencies and believable, and the creativity is unleashing the creativity for the designers and for the brands.W why is no one else doing this? Or are they well, uh, there are some, uh, companies, our customers that using our technologies like Amazon are doing it. If you go to Amazon and you're doing what you're doing, right. That's what I meant because, well, we are kind of unique festival in terms of the physical world.We out technology, what we have developed is systems Inc services that is all sustainable, which are digital systems that can produce one off. If you want it to produce a t-shirt or any, any government or any fabric in the, in, in the past using analog technology, you had to print where to produce hundreds of meters in order that it will be economical and.The sustainability impact is huge. Um, there's a lot of pollution and consumption of water for every meter without technology, because it's digital, you are not limited. You can print one t-shirt, you can print one meter, one fit, there's no limitation and every feed can be different design. So this is the advantage of digital is unleashing the limitations that you had before, and we are not using water.So there's no, there's no water consumption. It's pigment ink. So it's fully green. So no impact on the environment. So like who couldn't use corny Amazon obviously, but they're the largest retailer in the world could, could, could I use it on my online Shopify store that make, that sells? I dunno, 10 shirts a year.Exactly the point it's off form. The biggest retailers, biggest e-commerce biggest brands like Adidas, Nike. They of course can use it to anyone, any consumer that would like to open a shop in Shopify. Now, what is the problem with Shopify? If you are now at this time? And you see somewhere in India and you would like to, to sell your product.You open the shop in Shopify in five minutes, you put your design, what is the problem? Once you get the order, what are you going to do with it? How are you going to produce it? Are you going to ship it out? We can compete against other marketplaces. What call Nita Naples is to connect all those and marketplaces all those designers in to a network of fulfiller that can fulfill for them.So you need to take care of only on the design, open a shop, and then connected to Coney ticks. And kinetics is a platform that connect them to a network or fulfiller that using our technology and can produce it anywhere around the world. And it sounds good. The market clearly likes it. Cause if you, if you look at your stock, it's had a pretty tremendous run actually, even, even last year, uh, seemed to, uh, COVID, didn't seem to hold it down too long.So, uh, the market agrees with you. Uh, so I, I guess keep doing what you're doing. Uh, running Samuel was the CEO of, uh, coordinate, uh, digital. Uh, we will have to get you back on the show. Uh, hopefully, uh, now maybe next year when, when the supply chain starts to work itself out a little bit, but I, I I'm, I'm very curious about this space because, uh, you're, you're one of the best performing stocks, uh, I think out there probably right now.So, uh, Ronan, thank you so much for coming on the show today. Thank you very much. Pleasure being here. All right. Uh, it is, uh, 1259. We've got our next guest coming on in couple minutes. Whenever minute when it, whenever they join, to be honest, cause they're not even here yet, but that's okay. Uh, Scott Mathis is the CEO and chairman of Gacha holdings, ticker V I N L a.And then we have, I'm very excited for our one to 30 guests, but we're not a Capels from Benzinga and, uh, really Benzinga is, is a side it's his side gig. His main gig is, uh, is doing really complex. Trading stuff, strategies. So, uh, I'm, I'm very, I'm very much looking forward to that, uh, in a half hour. Uh, if we can think of who executive though, and I have not grabbed, voted for likes yet this hour as we enter our two of our show keyword yet, uh, if you could be so kind and hit that thumbs up button on your screen, I'm not sure where we're at on the light counter right now.Let's look, we're at the de come on computer 74, 75. We can do better than that. We do over a hundred easy, easy. The goal for the goal for the day is 200, but we can get you a hundred right now. I suspect. Yeah. So before we get to Scott Mathis with a wild show holdings, um, the, uh, the previous guest, I liked that idea of cause basically what he's saying is that companies now are producing clothes for a year down the line, right?But they don't know what's going to be hot on Instagram and Tik TOK and what the trends are going to be efficient. It's not efficient. So what, what he's saying they're doing is waiting and basically it's print on demand, but on a huge scale, like what Shelly was talking about in the chat with the economies of scale, they're able to produce, uh, the goods for cheaper when they're doing it on a large scale.If everyone, if they're, if their technology is able to kind of shift that whole industry, it would have a tremendous impact on, uh, the environmental right now, the negative environmental impact that the textile industry has. Another fun fact. Spencer, did you know this, that a lot of luxury brands, um, such as, you know, Gucci, Louis Vuitton, do you know what they do with their extra extra goods?No, I don't want to say something that's politically incorrect, but I know I have no idea. What could, what would the, I don't know. They, they, they, they give it the, give it to animals. I don&

While nary a day goes by without a shovel breaking ground on a new CDMO buildout, biopharmas remain hard-pressed to secure the outsourced manufacturing space and expertise needed to meet timelines, satisfy investors, and drive competitive advantage. On this episode of the Business of Biotech, we're tackling the CDMO capacity crunch from every angle in a spirited discussion with Discovery Labs & Center for Breakthrough Medicines Co-Founder Audrey Greenberg, Iovance SVP of Commercial Manufacturing Sumit Verma, and Project Farma CEO Anshul Mangal.

The discovery and cell line development of biotherapeutics has been traditionally a distinct process. Absci is taking what it describes as a more wholistic approach by collapsing the process down and addressing the functionality and manufacturability of therapeutic candidates simultaneously. We spoke to Sean McClain, founder and CEO of AbSci, about how it is using AI and synthetic biology to reinvent the discovery process, how this is expanding the therapeutic potential of proteins, and how it translates into time and cost benefits.

Carl Quintanilla, Jim Cramer and David Faber kick off a new month and quarter by announcing details about Cramer launching the "CNBC Investing Club," which aims to help investors build long-term wealth. A big story out of Merck: The stock surging after the drug maker and its partner Ridgeback Biotherapeutics announced their experimental COVID-19 pill cut the risk of death and hospitalization by 50% in a late stage study. Both companies plan to file for emergency use authorization as soon as possible. Ridgeback Co-Founder Dr. Wayne Holman and Co-Founder and CEO Wendy Holman joined the program to discuss this big development in the war against the pandemic. Also in focus: Zoom Video and Five9 have terminated their nearly $15-billion deal by mutual consent, what to expect from the markets in the fourth quarter after a rough September, Exxon Mobil expects higher oil and gas prices to boost quarterly earnings by as much as $1.5-billion -- and Cathie Wood tweets about peak oil demand.

Tracy discusses navigating pediatric cancer on behalf of her daughter Sophie and dedicating her life to educating herself and wider communities on the medicinal powers of cannabis.

Emendo was founded in 2015 by Rachel and a group of classmates from Weizmann. Her role at Emendo as Chief Intellectual Property Officer & Head of Pipeline Development includes building is to design an IP strategy for Emendo that both generates an extensive patent portfolio to cover various novel aspects of the technology and products and also navigates the IP space. Additionally, she is building Emendo's pipeline of clinical programs and the academic and industrial collaborations and partnerships for the pre/clinical development of Emendo's selected indications and genomic targets.

Grant is the Chief Business Officer with Bolt BioTherapeutics. Bolt Bio recently went public in February this year and announced a partnership with Genmab. Grant talks business development strategy and helping to navigate Bolt through their recent milestones.Bolt Bio focuses on the development of ISACs – immune-stimulating antibody conjugates – which are anti-cancer drugs comprised of two main parts: a tumor targeting antibody attached to an immune system stimulant. This stimulant activates both the innate and adaptive arms of the immune system, potentially turning a “cold” tumor environment into a “hot” one. Their lead therapeutic candidate, BDC-1001, targets HER2+ tumors and is currently in Phase 1/2 trials.https://www.boltbio.com/ https://www.globenewswire.com/news-release/2021/06/02/2240329/0/en/Genmab-and-Bolt-Biotherapeutics-Announce-Oncology-Research-and-Development-Collaboration.html

Dr. James Tursi, MD, Chief Scientific Officer of Ferring Pharmaceuticals discusses developments in microbiome-based therapeutics for the treatment of recurrent C. difficile (rCDI) infection. The current standard of care treatment for rCDI is currently antibiotics. While they are important, they do not restore the underlying health of the gut microbiome, nor can they stop C. diff​icile​ spores from growing back. He talks about what their late stage pivotal Phase 3 clinical trial results showed regarding mitigating recurrent C. difficile infection.​ ​The ​gut ​microbiome is an emerging area where biotherapeutics are being developed to address certain diseases and conditions.​ #FerringPharmaceuticals #ClostridioidesDifficileInfection Dr. James Tursi is responsible for U.S. Clinical Development, Pharmaceutical Development, Medical Affairs, Pharmacovigilance (PV), Project Planning and Regulatory Affairs. James collectively has over 30 years of experience in medicine and nearly 20 years in the pharmaceutical industry. Prior to joining Ferring, as Executive Vice President, R&D, Chief Medical Officer for Antares Pharmaceuticals, he created patent extension and portfolio opportunities, was the medical-clinical-PV lead for commercial and business development activities and designed the medical/clinical commercial strategies. Before joining Antares, James held positions of increasing responsibility at Aralez Pharmaceuticals, Auxilium Pharmaceuticals, GlaxoSmithKline, and Procter & Gamble Pharmaceuticals. His therapeutic expertise includes reproductive health, urology, endocrinology (including pediatric), gastroenterology, cardiology, vascular surgery, oncology and neurology. He practiced medicine and surgery for over 10 years and created a medical education company, I Will Pass ®, which assisted physicians in the process of board certification. James holds a Bachelor of Science degree in Chemistry and Biology from Ursinus College; a Doctor of Medicine from Medical College of Pennsylvania and performed his residency in Gynecology and Obstetrics at the Johns Hopkins Hospital.

Beverly Mok is a graduate student in Chemistry and Chemical Biology at Harvard University. She is currently working in the complex field of genes and genomics focusing on genome editing in the David Liu Lab. She is also involved in the development of programmable tools to perform detailed and accurate modifications on the human genome. Current tools do a double-stranded break which the cell may try to resolve in a way that may not be ideal. Once the break happens, the cells resolve the break in two ways. They make repairs by insertions or deletions which is not ideal. Or they supply a template DNA that undergoes homogenous DNA repair back to the original sequence to precisely repair the DNA. Base editing is a new way of targeting and repairing faulty genes. The new genome editing techniques do not use double-strand breaks. The benefits of the base editing approach is that it facilitates precise genome editing and minimizes undesired by-products and toxicity associated with the double-strand breaks in DNA. Click on play to learn about: How CRISPR-Cas9 is used to edit parts of the genome. A new process of base editing that does not introduce double-strand breaks. How the new process achieves exquisite levels of specificity with base editing. What genetic diseases are being considered for future studies involving base editing. Mok is participating in studies to identify possible next generation biotherapeutics and genome editing techniques that have the potential to treat and possibly cure genetic diseases like Huntington's disease, blood cancers, and cystic fibrosis. She applies chemical biology strategies to genome editing to advance the capabilities and safety of genome-engineering proteins. To learn more visit: https://liugroup.us David R. Liu @davidrliu liugroup @liugroup Episode also available on Apple Podcasts: apple.co/30PvU9C

Jonathan Rigby is an experienced CEO with three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry. He currently serves as the CEO of Revolo Biotherapeutics, a biotechnology company setting out to revolutionize the treatment for autoimmune and allergic diseases, through the development of therapies that reset the immune system to achieve superior long-term disease remission. Prior to leading the charge at Revolo, Mr. Rigby established SteadyMed Therapeutics Inc. and focused the company on the development of drug device combination products to treat Pulmonary Hypertension. As the CEO, he led the company through a Nasdaq listing in 2015(Nasdaq: STDY) and a public-to-public company sale to United Therapeutics (Nasdaq: UTHR)in late 2018. In 2006 he co-founded Zogenix, Inc. (Nasdaq: ZGNX) a specialty pharmaceutical company now focused on the development and commercialization of drug products to treat rare diseases and was instrumental in its listing on Nasdaq in 2010. Earlier in his career, Jonathan held commercial and business development positions of increasing responsibility at large pharmaceutical companies including Merck and Bristol Myers Squibb and Profile Therapeutics, now Phillips Medical. Jonathan has served as Executive Board Member at SteadyMed Ltd. (Nasdaq: STDY), Non-Executive Board Member at Xeris Pharmaceuticals (Nasdaq: XERS) and Chairman of the Board at CollPlant Biotechnologies (Nasdaq: CLGN). He holds a Bachelor of Science Degree with Honors in Biological Sciences from Sheffield University, UK, and an MBA from Portsmouth University, UK.

Is Lionsgate (LGF.A) the next Netflix? Or the next Disney+? Marcus Moore of Zeo Capital Advisors explains why he see's a new streaming content king. Take-Two Interactive (TTWO) reveals some of its post-pandemic strategy with a plan to launch 60 news games over the next three years. Bitcoin, Ether and XRP take a dive. Iovance Biotherapeutics (IOVA) bungles tests for a potential cancer cure, a failed drug test and a CEO headed for the exits. And the Container Store (TCS) hunts for a way to keep up with its stellar pandemic-era sales and remains in the closet. The Drill Down with Cory Johnson offers a daily look at the business stories behind stocks on the move. Learn more about your ad choices. Visit megaphone.fm/adchoices

On today’s podcast, Jimmy El Hokayem, Head of the Neurology and Regenerative Medicine Centers of Excellence and Associate Director of Program Development at Biorasi, will be talking with Paula Evans, CEO and Co-Founder of GeneTx Biotherapeutics.

Sean McClain is the Founder and CEO of AbSci, a synthetic biology company that uses a patented Protein Printing™ technology to transform traditional biomanufacturing and drug discovery. Sean has spent his career investigating and developing technologies that drive down drug costs, speed up drug development, and enable the manufacture of next-generation biotherapeutics that wouldn't make it to market otherwise. Under Sean's leadership, AbSci has grown to more than 100 employees, raised more than $100 million in capital, and has established partnerships with industry-leading pharmaceutical companies to develop biomanufacturing technologies for life-saving drugs. In 2019, Sean was recognized by Forbes as part of the “30 Under 30 in Science” cohort, and he was named as an “Entrepreneur Of The Year® 2020 Pacific Northwest Region Award Winner.” Sean also serves as a board member for the Oregon Bioscience Association, the Oregon Bioscience Incubator and OTRADI, and Life Science Washington. Sean is a graduate of the University of Arizona, where he studied biochemistry and molecular biology. In this episode… Can technology help speed up the process for drug development? How is biomanufacturing hoping to help in the fight against disease? Have you heard of AbSci, the company being heralded as the Google of synthetic biology? Meet Sean McClain, the Founder and CEO of AbSci and the visionary behind next-generation biotherapeutics. He started his company in 2011 with a determination to question what's possible and believe in the impossible. Now, Sean's innovations have him pioneering the way forward and questioning what the future might hold. If you're curious about the exciting things taking place in the world of biomanufacturing, this episode is for you! In this episode of the Measure Success Podcast, Carl J. Cox sits down with Sean McClain, Founder and CEO of AbSci, to learn about what's revolutionizing the field of biomanufacturing. Sean describes how AbSci is speeding up the process of drug development, what he's doing to keep up with his company's drastic growth, and why a severe accident inspired him to make some changes. Plus, Sean divulges some of his plans for the future of synthetic biology. Stay tuned!

Usama Malik, CEO, Fore Biotherapeutics is aiming to treat patients with rare cancer mutations with a hyper targeted precision or personalized approach by using the Fore AI-based technology platform to investigate which drugs might work best for each mutation. While most cancer companies focus only on the most prevalent mutations, Fore is expanding the search by looking at hundreds of mutations to identify driver mutations that actively contribute to the growth of tumors. Fore is in search of unaddressed patient populations and patients where existing therapeutics are not working. #ForeBiotherapeutics #cancer #raredisease #oncology #BRAF #precisionmedicine #personalizedmedicine #DriverMutations Fore.Bio Download the transcript here

Usama Malik, CEO, Fore Biotherapeutics is aiming to treat patients with rare cancer mutations with a hyper targeted precision or personalized approach by using the Fore AI-based technology platform to investigate which drugs might work best for each mutation. While most cancer companies focus only on the most prevalent mutations, Fore is expanding the search by looking at hundreds of mutations to identify driver mutations that actively contribute to the growth of tumors. Fore is in search of unaddressed patient populations and patients where existing therapeutics are not working. #ForeBiotherapeutics #cancer #raredisease #oncology #BRAF #precisionmedicine #personalizedmedicine #DriverMutations Fore.Bio Listen to the podcast here

Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others have not been able to reach. Revolo Bio's platform drug candidates '1805 and '1104 are in development for rheumatoid arthritis, uveitis, eosinophilic esophagitis and allergic diseases. @RevoloBio #AutoimmuneDisease #AllergicDisease #RheumatoidArthritis #Uveitis #EosinophilicEsophagitis RevoloBio.com Download the transcript here

Jonathan Rigby, CEO, Revolo Biotherapeutics discusses the company's revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, with less frequent chronic dosing and without suppression of the immune system. A goal that others have not been able to reach. Revolo Bio's platform drug candidates '1805 and '1104 are in development for rheumatoid arthritis, uveitis, eosinophilic esophagitis and allergic diseases. @RevoloBio #AutoimmuneDisease #AllergicDisease #RheumatoidArthritis #Uveitis #EosinophilicEsophagitis RevoloBio.com Listen to the podcast here

Heute Palantir, Riot Blockchain, Bionomics und Sensei Biotherapeutics.

There are no bad ideas in developing bioanalytical testing, says Jim McNally, CSO of BioAgilytix. Not all ideas will work, of course. But he has found that it is the outside-the-box ideas that often turn out to be the solution in challenging assay work. Dr. McNally speaks with The Chain about his background in bioanalytical testing and supporting clinical trials, the exciting future of cell and gene therapies, and the importance of setting precedent in bioanalysis of these new, life-saving therapies. It is an exciting time for gene therapy especially, and Dr. McNally shares how new immunogenicity data is getting us closer to bringing this therapy to more people.

Bolt Biotherapeutics CMO Dr. Edith Perez and VP of CMC & Quality Dr. Nathan Ihle bring a unique combination of patient and production process expertise to the table for an enlightening conversation on preparing chemistry, manufacturing, and controls for an IND and ensuing first in-human studies.

Dr. Randy Schatzman, Ph.D., is the chief executive officer and a board member of Bolt Biotherapeutics since 2019. He has over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer-reviewed scientific publications.

Salubris Biotherapeutics Co-founder Samuel Murphy shares his thoughts about leadership in biopharma with BioBoss host John Simboli. Samuel also discusses Salubris Biotherapeutics advances in therapeutics for the treatment of cancer, cardiovascular, and metabolic diseases.

Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer.  The Boltbody™ platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight cancer.  Bolt's preclinical data show that in addition to killing the tumor, there is an immunological memory which helps to prevent tumors from growing back.  Dr. Perez also discusses Bolt's first target HER2-expressing cancers, how the Boltbody™ platform is overcoming challenges treating this cancer and Bolt's current Phase 1 clinical trial. @BoltBio  #HER2  #Cancer  #Boltbody BoltBio.com Download the transcript here.

Dr. Edith Perez, Chief Medical Officer, Bolt Biotherapeutics discusses an innovative new platform for the treatment of patients with cancer.  The Boltbody™ platform uses a combination of tumor targeting antibodies and localized stimulation of the immune system, or immune stimulating antibody conjugates, to fight cancer.  Bolt's preclinical data show that in addition to killing the tumor, there is an immunological memory which helps to prevent tumors from growing back.  Dr. Perez also discusses Bolt's first target HER2-expressing cancers, how the Boltbody™ platform is overcoming challenges treating this cancer and Bolt's current Phase 1 clinical trial. @BoltBio  #HER2  #Cancer  #Boltbody BoltBio.com Listen to the podcast here.

Eddie Sullivan, President, CEO, Co-Founder, SAb Biotherapeutics talks about their innovative technology to generate targeted highly potent immunotherapies on a large scale.  SAb is producing fully human polyclonal antibodies targeted to COVID-19 without the need for convalescent plasma blood donations by using genetically engineered cattle which produce the fully human antibodies. @SABBantibody  #COVID19 #immunotherapies #antibodies SAbbiotherapeutics.com/covid-19 Listen to the podcast here

Eddie Sullivan, President, CEO, Co-Founder, SAb Biotherapeutics talks about their innovative technology to generate targeted highly potent immunotherapies on a large scale.  SAb is producing fully human polyclonal antibodies targeted to COVID-19 without the need for convalescent plasma blood donations by using genetically engineered cattle which produce the fully human antibodies. @SABBantibody  #COVID19 #immunotherapies #antibodies SAbbiotherapeutics.com/covid-19 Download the transcript here

Subcutaneous (SC) delivery has become the norm for treating diseases such as Rheumatoid arthritis and multiple sclerosis, and there remains great potential to offer home- or even self-administered SC delivery for several other biotherapeutics. Given that there are a number of products already on the market, they can be examined to understand what improvements and changes can be made to increase product development opportunities and also enhance the patient experience. In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, you will hear from clinicians (pharmacist and physician) and industry to gain insight into needs and preferences of future SC biotherapeutic formulations and devices. For example, panelists will address the issue of reducing costs and dose complexity, improving adherence, and also provide input on changes they would like to see in future SC biotherapeutic products. Moderated by: Dr Beate Bittner, Roche Panelists include: Dr Mary Nauffal, Brigham and Women's HospitalDr Manuel Sanchez-Felix, Novartis Institutes for BioMedical ResearchDr Anand Subramony, AstraZenecaDr David Ting, MGH Cancer Center/Harvard Medical School To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

"To run a good drug development program or to do good academic research, you just need excellent science. However there are different pressures and expectations that come with the two different settings." Mihri Tuna is the Chief Scientific Officer of Adaptate Biotherapeutics, a company she joined recently after a track record of success in early stage, high growth biotechs. In this episode, you'll hear Mihri's views on:

This episode continues our celebration of Women’s History Month. Dr. Emily English, Gemstone Biotherapeutics CEO, discusses her path from bench scientists to entrepreneur and where her interest in STEM began. Follow the Festival on Twitter & Instagram at @mdstemfest, on Facebook @marylandstemfestival and on our website www.marylandstemfestival.org. Follow Gemstone Gemstone Biotherapeutics at http://www.gemstonebio.com/

Some scientists dream of genes. Cenk Ündey dreams of intelligent data flow through the value-added chain of biotherapeutic protein development. Ündey is an Executive Director of Process Development at Amgen. He sits down with The Chain to describe a system of streamlined and effective data management at every step: From molecule delivery to working with suppliers. Thanks to advanced computing power, broader datasets, and improved storage, this dream is closer to realization than ever before.

If the researchers, executives and investors behind Coda Biotherapeutics have their way, one day soon there really could be a cure for pain. Co-founded by researchers Joseph Glorioso, from the University of Pittsburgh's microbiology and molecular genetics department; and Dr. Nicholas Boulis, the founder of Emory's Gene and Cell Therapy for Neurorestoration Laboratory; Coda uses gene therapies to treat neurological diseases starting with severe pain and epilepsy.

Over fifty years since its first use, Dr. Marco Casteleijn breaks down the resurgence of cell-free protein synthesis and its application across industries, including VTT’s research of cell-free proteins for pharma and the fashion industry. Plus, we discuss the importance of science writing to describe discoveries and communicate findings with funders and the public.

Gemstone Biotherapeutics CEO Emily English joins Rich Bendis on BioTalk to discuss the company's history, the path to her role, and the evolution of their technology

Dr. Florian M. Wurm, Swiss Federal Institute of Technology Lausanne (EPFL) and ExcellGene SA speaks to Cambridge Healthtech Institute on 9 July 2018. He will be the keynote presenter during the Optimising Expression Platforms conference at PEGS Europe, 12-16 November 2018 in Lisbon, Portugal. For more information, please visit http://www.PEGSummitEurope.com/Optimising-Protein-Expression Topics Questions Include: Let's talk about transient protein expression. What advances do you foresee in this approach for enabling efficient engineering and expression of therapeutic proteins in the next decade? What potential solutions seem promising for some … challenges? Are there promising glimpses into using transient protein gene expression for clinical use today? You'll be discussing “Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing” during your keynote presentation on 14 November. What's the main theme you'd like to convey to your audience of protein engineers and researchers?

Axial biotherapeutics is a biopharmaceutical company developing new therapeutics to treat diseases of the central nervous system. According to Dr. David Donabedian, CEO, and co-founder, researchers hope to leverage the link between the human gut microbiome and central nervous system including Autism and Parkinson's Disease. While there are many factors that have contributed to an increase in the number of children with symptoms of autism, Dr. Donabedian suggests that environmental factors may have caused changes in the diversity of bacteria that children are exposed to. Therefore, Axial has taken a unique approach by focusing on the gut-brain axis. Initial testing at Axial has shown that gut-selective therapies have resulted in improvements in core behaviors and symptoms associated with autism as well as reducing symptoms due to gastrointestinal disorders.

A podcast interview with PEGS speaker David Weis of the University of Kansas. Dr. Weis is speaking in the Biophysical Analysis of Biotherapeutics meeting, where he will give a presentation on the topic “Hydrogen Exchange Mass Spectrometry in Formulation Development and Similarity Assessment”

Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and is a fellow of the Royal Society of Canada.

Mauro Giacca, ICGEB, Trieste - ITALY speaks on "Disease Models and Translation 8: The mouse as a tool for the development of novel biotherapeutics for cardiovascular disorders". This seminar has been recorded at ICTP Trieste by ICGEB Trieste

This podcast presents an interview with Dr. John Kellie, an Investigator in the Bioanalytical Sciences and Toxicokinetics group at GlaxoSmithKline, and a speaker in the Characterization of Biotherapeutics meeting at the 11th Annual PEGS Boston. John explains how next-generation analytical technologies are being used to characterize circulating ADC species, and how these findings support the development of safe and effective antibody-drug conjugate therapeutics. To learn more, visit http://www.PEGSummit.com/Biotherapeutics-Characterization

Nandini Kashyap interviews Dr. Johnson Varghese of Shire HGT on October 1, 2014. Dr. Varghese will be speaking during the Characterization of ADCs, Bispecifics and New Biotherapeutics conference taking place on January 19th-20th at the upcoming PepTalk event which runs from January 19th to 23rd, 2015 in San Diego, CA.

A discussion with Drs. Nancy Everds, Nianyu Li and Katherine Sprugel from Amgen in Seattle, Washington about the article “Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody”.  This manuscript won the journal’s best paper award in 2013 and describes a study that is a cautionary tale for those investigating/testing monoclonal antibodies.   Click here to read the full article.  

Mauro Giacca, ICGEB, Molecular Medicine, Group Leader, Trieste - ITALY speaks on "Disease Models and Translation: The mouse as a tool for the development of novel biotherapeutics for cardiovascular disorders". This seminar has been recorded at ICTP Trieste by ICGEB Trieste

Guest: Ronald Sherman Host: Bill Rutenberg, MD Join host Dr. Bill Rutenberg as he discusses the magical mysteries of the wound debridement biotherapy with our guest Dr. Ronald Sherman, director of the non-profit BioTherapeutics, Education & Research Foundation. Learn about the medical uses for maggots, how maggot therapy is executed and what controlled studies show about the use of medical grade maggots.

Through research, clinical trials and biomanufacturing, Mayo Clinic's Center for Regenerative Biotherapeutics is working to develop new types of medicines derived from the human body to treat chronic and age-related diseases. Biologics are therapies that come from human sources — cells, blood, enzymes, tissues, genes or genetically engineered cells — for use in medicines. Biomanufacturing is focused on manufacturing commercial grade biologically based medicines for treatment. Some examples include the use of stem cells, gene therapy and cell therapy, and 3D printing of tissues and organs."The important thing is that there's an opportunity to use these type of therapies to cure rather than just treat patients as we move forward looking at different ways of being able to use these products," says Dr. Julie Allickson, the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics. "It's definitely a bright future." Dr. Allickson also is the Otto Bremer Trust Director of Biomanufacturing and Product Development in the Center for Regenerative Biotherapeutics.Mayo Clinic is working to move cellular discoveries from the lab to clinical trial and into commercially available therapies. To move technologies forward, partnerships are key.  Mayo Clinic has formed a strategic collaboration with National Resilience Inc. to establish Rochester, Minnesota as a center for biomanufacturing regenerative technologies. Mayo also has manufacturing facilities in Jacksonville, Florida and Phoenix.Recently, Mayo Clinic, Hibiscus BioVentures, and Innoforce announced the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet patient needs. All three organizations have a financial interest in the Mayflower collaboration. Mayo Clinic will use any revenue it receives to support its nonprofit mission in patient care, education and research."There is a lot of investment in the field," says Dr. Allickson. "And Mayo Clinic is certainly prioritizing this across the enterprise, to allow the patients here to have treatments focused on rare and complex diseases. Here at Mayo Clinic, we want to make sure that that happens."On the Mayo Clinic Q&A podcast, Dr. Allickson discusses the near- and long-term future of biomanufacturing and biotherapeutics. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy